Motif 1040 (n=85)
Position-wise Probabilities
Download
| uniprot | genes | site | source | protein | function |
|---|---|---|---|---|---|
| A5A3E0 | POTEF | Y791 | ochoa | POTE ankyrin domain family member F (ANKRD26-like family C member 1B) (Chimeric POTE-actin protein) | None |
| A6NMY6 | ANXA2P2 | Y238 | ochoa | Putative annexin A2-like protein (Annexin A2 pseudogene 2) (Lipocortin II pseudogene) | Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress response. {ECO:0000250}. |
| O00507 | USP9Y | Y368 | ochoa | Ubiquitin carboxyl-terminal hydrolase 9Y (EC 3.4.19.12) (Deubiquitinating enzyme FAF-Y) (Fat facets protein-related, Y-linked) (Ubiquitin thioesterase FAF-Y) (Ubiquitin-specific protease 9, Y chromosome) (Ubiquitin-specific-processing protease FAF-Y) | Deubiquitinase that mediates deubiquitination of target proteins (PubMed:12895410). May stabilize target proteins that are important for male germ cell development (PubMed:12895410). {ECO:0000269|PubMed:12895410}. |
| O14757 | CHEK1 | Y390 | ochoa | Serine/threonine-protein kinase Chk1 (EC 2.7.11.1) (CHK1 checkpoint homolog) (Cell cycle checkpoint kinase) (Checkpoint kinase-1) | Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA (PubMed:11535615, PubMed:12399544, PubMed:12446774, PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15650047, PubMed:15665856, PubMed:32357935). May also negatively regulate cell cycle progression during unperturbed cell cycles (PubMed:11535615, PubMed:12399544, PubMed:12446774, PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15650047, PubMed:15665856). This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome (PubMed:11535615, PubMed:12399544, PubMed:12446774, PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15650047, PubMed:15665856). Recognizes the substrate consensus sequence [R-X-X-S/T] (PubMed:11535615, PubMed:12399544, PubMed:12446774, PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15650047, PubMed:15665856). Binds to and phosphorylates CDC25A, CDC25B and CDC25C (PubMed:12676583, PubMed:12676925, PubMed:12759351, PubMed:14559997, PubMed:14681206, PubMed:19734889, PubMed:9278511). Phosphorylation of CDC25A at 'Ser-178' and 'Thr-507' and phosphorylation of CDC25C at 'Ser-216' creates binding sites for 14-3-3 proteins which inhibit CDC25A and CDC25C (PubMed:9278511). Phosphorylation of CDC25A at 'Ser-76', 'Ser-124', 'Ser-178', 'Ser-279' and 'Ser-293' promotes proteolysis of CDC25A (PubMed:12676583, PubMed:12676925, PubMed:12759351, PubMed:14681206, PubMed:19734889, PubMed:9278511). Phosphorylation of CDC25A at 'Ser-76' primes the protein for subsequent phosphorylation at 'Ser-79', 'Ser-82' and 'Ser-88' by NEK11, which is required for polyubiquitination and degradation of CDCD25A (PubMed:19734889, PubMed:20090422, PubMed:9278511). Inhibition of CDC25 leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression (PubMed:9278511). Also phosphorylates NEK6 (PubMed:18728393). Binds to and phosphorylates RAD51 at 'Thr-309', which promotes the release of RAD51 from BRCA2 and enhances the association of RAD51 with chromatin, thereby promoting DNA repair by homologous recombination (PubMed:15665856). Phosphorylates multiple sites within the C-terminus of TP53, which promotes activation of TP53 by acetylation and promotes cell cycle arrest and suppression of cellular proliferation (PubMed:10673501, PubMed:15659650, PubMed:16511572). Also promotes repair of DNA cross-links through phosphorylation of FANCE (PubMed:17296736). Binds to and phosphorylates TLK1 at 'Ser-743', which prevents the TLK1-dependent phosphorylation of the chromatin assembly factor ASF1A (PubMed:12660173, PubMed:12955071). This may enhance chromatin assembly both in the presence or absence of DNA damage (PubMed:12660173, PubMed:12955071). May also play a role in replication fork maintenance through regulation of PCNA (PubMed:18451105). May regulate the transcription of genes that regulate cell-cycle progression through the phosphorylation of histones (By similarity). Phosphorylates histone H3.1 (to form H3T11ph), which leads to epigenetic inhibition of a subset of genes (By similarity). May also phosphorylate RB1 to promote its interaction with the E2F family of transcription factors and subsequent cell cycle arrest (PubMed:17380128). Phosphorylates SPRTN, promoting SPRTN recruitment to chromatin (PubMed:31316063). Reduces replication stress and activates the G2/M checkpoint, by phosphorylating and inactivating PABIR1/FAM122A and promoting the serine/threonine-protein phosphatase 2A-mediated dephosphorylation and stabilization of WEE1 levels and activity (PubMed:33108758). {ECO:0000250|UniProtKB:O35280, ECO:0000269|PubMed:10673501, ECO:0000269|PubMed:11535615, ECO:0000269|PubMed:12399544, ECO:0000269|PubMed:12446774, ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676925, ECO:0000269|PubMed:12759351, ECO:0000269|PubMed:12955071, ECO:0000269|PubMed:14559997, ECO:0000269|PubMed:14681206, ECO:0000269|PubMed:14988723, ECO:0000269|PubMed:15311285, ECO:0000269|PubMed:15650047, ECO:0000269|PubMed:15659650, ECO:0000269|PubMed:15665856, ECO:0000269|PubMed:16511572, ECO:0000269|PubMed:17296736, ECO:0000269|PubMed:17380128, ECO:0000269|PubMed:18451105, ECO:0000269|PubMed:18728393, ECO:0000269|PubMed:19734889, ECO:0000269|PubMed:20090422, ECO:0000269|PubMed:31316063, ECO:0000269|PubMed:32357935, ECO:0000269|PubMed:33108758, ECO:0000269|PubMed:9278511}.; FUNCTION: [Isoform 2]: Endogenous repressor of isoform 1, interacts with, and antagonizes CHK1 to promote the S to G2/M phase transition. {ECO:0000269|PubMed:22184239}. |
| O14976 | GAK | Y412 | psp | Cyclin-G-associated kinase (EC 2.7.11.1) (DnaJ homolog subfamily C member 26) | Associates with cyclin G and CDK5. Seems to act as an auxilin homolog that is involved in the uncoating of clathrin-coated vesicles by Hsc70 in non-neuronal cells. Expression oscillates slightly during the cell cycle, peaking at G1 (PubMed:10625686). May play a role in clathrin-mediated endocytosis and intracellular trafficking, and in the dynamics of clathrin assembly/disassembly (PubMed:18489706). {ECO:0000269|PubMed:10625686, ECO:0000269|PubMed:18489706}. |
| O75369 | FLNB | Y1687 | ochoa | Filamin-B (FLN-B) (ABP-278) (ABP-280 homolog) (Actin-binding-like protein) (Beta-filamin) (Filamin homolog 1) (Fh1) (Filamin-3) (Thyroid autoantigen) (Truncated actin-binding protein) (Truncated ABP) | Connects cell membrane constituents to the actin cytoskeleton. May promote orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Various interactions and localizations of isoforms affect myotube morphology and myogenesis. Isoform 6 accelerates muscle differentiation in vitro. |
| O95425 | SVIL | Y1317 | ochoa | Supervillin (Archvillin) (p205/p250) | [Isoform 1]: Forms a high-affinity link between the actin cytoskeleton and the membrane. Is among the first costameric proteins to assemble during myogenesis and it contributes to myogenic membrane structure and differentiation (PubMed:12711699). Appears to be involved in myosin II assembly. May modulate myosin II regulation through MLCK during cell spreading, an initial step in cell migration. May play a role in invadopodial function (PubMed:19109420). {ECO:0000269|PubMed:12711699, ECO:0000269|PubMed:19109420}.; FUNCTION: [Isoform 2]: May be involved in modulation of focal adhesions. Supervillin-mediated down-regulation of focal adhesions involves binding to TRIP6. Plays a role in cytokinesis through KIF14 interaction (By similarity). {ECO:0000250|UniProtKB:O46385}. |
| P00367 | GLUD1 | Y451 | ochoa | Glutamate dehydrogenase 1, mitochondrial (GDH 1) (EC 1.4.1.3) | Mitochondrial glutamate dehydrogenase that catalyzes the conversion of L-glutamate into alpha-ketoglutarate. Plays a key role in glutamine anaplerosis by producing alpha-ketoglutarate, an important intermediate in the tricarboxylic acid cycle (PubMed:11032875, PubMed:11254391, PubMed:16023112, PubMed:16959573). Plays a role in insulin homeostasis (PubMed:11297618, PubMed:9571255). May be involved in learning and memory reactions by increasing the turnover of the excitatory neurotransmitter glutamate (By similarity). {ECO:0000250|UniProtKB:P10860, ECO:0000269|PubMed:11032875, ECO:0000269|PubMed:11254391, ECO:0000269|PubMed:11297618, ECO:0000269|PubMed:16023112, ECO:0000269|PubMed:16959573, ECO:0000269|PubMed:9571255}. |
| P02549 | SPTA1 | Y548 | psp | Spectrin alpha chain, erythrocytic 1 (Erythroid alpha-spectrin) | Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane. |
| P05023 | ATP1A1 | Y542 | ochoa | Sodium/potassium-transporting ATPase subunit alpha-1 (Na(+)/K(+) ATPase alpha-1 subunit) (EC 7.2.2.13) (Sodium pump subunit alpha-1) | This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients (PubMed:29499166, PubMed:30388404). Could also be part of an osmosensory signaling pathway that senses body-fluid sodium levels and controls salt intake behavior as well as voluntary water intake to regulate sodium homeostasis (By similarity). {ECO:0000250|UniProtKB:Q8VDN2, ECO:0000269|PubMed:29499166, ECO:0000269|PubMed:30388404}. |
| P06239 | LCK | Y192 | ochoa|psp | Tyrosine-protein kinase Lck (EC 2.7.10.2) (Leukocyte C-terminal Src kinase) (LSK) (Lymphocyte cell-specific protein-tyrosine kinase) (Protein YT16) (Proto-oncogene Lck) (T cell-specific protein-tyrosine kinase) (p56-LCK) | Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated LCK protein to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAM) of the cytoplasmic tails of the TCR-gamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70, that becomes phosphorylated and activated by LCK. Following this, a large number of signaling molecules are recruited, ultimately leading to lymphokine production. LCK also contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, which leads to hyperphosphorylation and activation of LCK. Also plays a role in the IL2 receptor-linked signaling pathway that controls the T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR. Phosphorylates other substrates including RUNX3, PTK2B/PYK2, the microtubule-associated protein MAPT, RHOH or TYROBP. Interacts with FYB2 (PubMed:27335501). {ECO:0000269|PubMed:16339550, ECO:0000269|PubMed:16709819, ECO:0000269|PubMed:20028775, ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20851766, ECO:0000269|PubMed:21269457, ECO:0000269|PubMed:22080863, ECO:0000269|PubMed:27335501, ECO:0000269|PubMed:38614099}. |
| P06241 | FYN | Y214 | ochoa|psp | Tyrosine-protein kinase Fyn (EC 2.7.10.2) (Proto-oncogene Syn) (Proto-oncogene c-Fyn) (Src-like kinase) (SLK) (p59-Fyn) | Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance (PubMed:11536198, PubMed:15489916, PubMed:15557120, PubMed:16387660, PubMed:20100835, PubMed:7568038, PubMed:7822789). Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain (PubMed:15489916). Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions (PubMed:15489916). Involved in the regulation of cell adhesion and motility through phosphorylation of CTNNB1 (beta-catenin) and CTNND1 (delta-catenin) (PubMed:17194753). Regulates cytoskeletal remodeling by phosphorylating several proteins including the actin regulator WAS and the microtubule-associated proteins MAP2 and MAPT (PubMed:14707117, PubMed:15536091). Promotes cell survival by phosphorylating AGAP2/PIKE-A and preventing its apoptotic cleavage (PubMed:16841086). Participates in signal transduction pathways that regulate the integrity of the glomerular slit diaphragm (an essential part of the glomerular filter of the kidney) by phosphorylating several slit diaphragm components including NPHS1, KIRREL1 and TRPC6 (PubMed:14761972, PubMed:18258597, PubMed:19179337). Plays a role in neural processes by phosphorylating DPYSL2, a multifunctional adapter protein within the central nervous system, ARHGAP32, a regulator for Rho family GTPases implicated in various neural functions, and SNCA, a small pre-synaptic protein (PubMed:11162638, PubMed:12788081, PubMed:19652227). Involved in reelin signaling by mediating phosphorylation of DAB1 following reelin (RELN)-binding to its receptor (By similarity). Participates in the downstream signaling pathways that lead to T-cell differentiation and proliferation following T-cell receptor (TCR) stimulation (PubMed:22080863). Phosphorylates PTK2B/PYK2 in response to T-cell receptor activation (PubMed:20028775). Also participates in negative feedback regulation of TCR signaling through phosphorylation of PAG1, thereby promoting interaction between PAG1 and CSK and recruitment of CSK to lipid rafts (PubMed:18056706). CSK maintains LCK and FYN in an inactive form (By similarity). Promotes CD28-induced phosphorylation of VAV1 (PubMed:11005864). In mast cells, phosphorylates CLNK after activation of immunoglobulin epsilon receptor signaling (By similarity). Can also promote CD244-mediated NK cell activation (PubMed:15713798). {ECO:0000250|UniProtKB:P39688, ECO:0000269|PubMed:11005864, ECO:0000269|PubMed:11162638, ECO:0000269|PubMed:11536198, ECO:0000269|PubMed:12788081, ECO:0000269|PubMed:14707117, ECO:0000269|PubMed:14761972, ECO:0000269|PubMed:15536091, ECO:0000269|PubMed:15557120, ECO:0000269|PubMed:15713798, ECO:0000269|PubMed:16387660, ECO:0000269|PubMed:16841086, ECO:0000269|PubMed:17194753, ECO:0000269|PubMed:18056706, ECO:0000269|PubMed:18258597, ECO:0000269|PubMed:19179337, ECO:0000269|PubMed:19652227, ECO:0000269|PubMed:20028775, ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:22080863, ECO:0000269|PubMed:7568038, ECO:0000269|PubMed:7822789, ECO:0000303|PubMed:15489916}. |
| P07355 | ANXA2 | Y238 | ochoa | Annexin A2 (Annexin II) (Annexin-2) (Calpactin I heavy chain) (Calpactin-1 heavy chain) (Chromobindin-8) (Lipocortin II) (Placental anticoagulant protein IV) (PAP-IV) (Protein I) (p36) | Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress response. Inhibits PCSK9-enhanced LDLR degradation, probably reduces PCSK9 protein levels via a translational mechanism but also competes with LDLR for binding with PCSK9 (PubMed:18799458, PubMed:22848640, PubMed:24808179). Binds to endosomes damaged by phagocytosis of particulate wear debris and participates in endosomal membrane stabilization, thereby limiting NLRP3 inflammasome activation (By similarity). Required for endothelial cell surface plasmin generation and may support fibrinolytic surveillance and neoangiogenesis (By similarity). {ECO:0000250|UniProtKB:P07356, ECO:0000269|PubMed:18799458, ECO:0000269|PubMed:22848640, ECO:0000269|PubMed:24808179}.; FUNCTION: (Microbial infection) Binds M.pneumoniae CARDS toxin, probably serves as one receptor for this pathogen. When ANXA2 is down-regulated by siRNA, less toxin binds to human cells and less vacuolization (a symptom of M.pneumoniae infection) is seen. {ECO:0000269|PubMed:25139904}. |
| P07550 | ADRB2 | Y141 | psp | Beta-2 adrenergic receptor (Beta-2 adrenoreceptor) (Beta-2 adrenoceptor) | Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. {ECO:0000269|PubMed:2831218, ECO:0000269|PubMed:7915137}. |
| P07900 | HSP90AA1 | Y313 | psp | Heat shock protein HSP 90-alpha (EC 3.6.4.10) (Heat shock 86 kDa) (HSP 86) (HSP86) (Heat shock protein family C member 1) (Lipopolysaccharide-associated protein 2) (LAP-2) (LPS-associated protein 2) (Renal carcinoma antigen NY-REN-38) | Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity which is essential for its chaperone activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:11274138, PubMed:12526792, PubMed:15577939, PubMed:15937123, PubMed:27353360, PubMed:29127155). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself (PubMed:29127155). Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:26991466, PubMed:27295069). Plays a critical role in mitochondrial import, delivers preproteins to the mitochondrial import receptor TOMM70 (PubMed:12526792). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels (PubMed:25973397). In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues (PubMed:25973397). Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment (PubMed:25973397). Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205). Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation (PubMed:24613385). Mediates the association of TOMM70 with IRF3 or TBK1 in mitochondrial outer membrane which promotes host antiviral response (PubMed:20628368, PubMed:25609812). {ECO:0000269|PubMed:11274138, ECO:0000269|PubMed:11276205, ECO:0000269|PubMed:12526792, ECO:0000269|PubMed:15577939, ECO:0000269|PubMed:15937123, ECO:0000269|PubMed:20628368, ECO:0000269|PubMed:24613385, ECO:0000269|PubMed:25609812, ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:29127155, ECO:0000303|PubMed:25973397, ECO:0000303|PubMed:26991466, ECO:0000303|PubMed:27295069}.; FUNCTION: (Microbial infection) Seems to interfere with N.meningitidis NadA-mediated invasion of human cells. Decreasing HSP90 levels increases adhesion and entry of E.coli expressing NadA into human Chang cells; increasing its levels leads to decreased adhesion and invasion. {ECO:0000305|PubMed:22066472}. |
| P07910 | HNRNPC | Y105 | ochoa | Heterogeneous nuclear ribonucleoproteins C1/C2 (hnRNP C1/C2) | Binds pre-mRNA and nucleates the assembly of 40S hnRNP particles (PubMed:8264621). Interacts with poly-U tracts in the 3'-UTR or 5'-UTR of mRNA and modulates the stability and the level of translation of bound mRNA molecules (PubMed:12509468, PubMed:16010978, PubMed:7567451, PubMed:8264621). Single HNRNPC tetramers bind 230-240 nucleotides. Trimers of HNRNPC tetramers bind 700 nucleotides (PubMed:8264621). May play a role in the early steps of spliceosome assembly and pre-mRNA splicing. N6-methyladenosine (m6A) has been shown to alter the local structure in mRNAs and long non-coding RNAs (lncRNAs) via a mechanism named 'm(6)A-switch', facilitating binding of HNRNPC, leading to regulation of mRNA splicing (PubMed:25719671). {ECO:0000269|PubMed:12509468, ECO:0000269|PubMed:16010978, ECO:0000269|PubMed:25719671, ECO:0000269|PubMed:7567451, ECO:0000269|PubMed:8264621}. |
| P07947 | YES1 | Y223 | ochoa | Tyrosine-protein kinase Yes (EC 2.7.10.2) (Proto-oncogene c-Yes) (p61-Yes) | Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGFR, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signaling pathway and mediates AKT-mediated cell migration. Plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. Also involved in G2/M progression and cytokinesis. Catalyzes phosphorylation of organic cation transporter OCT2 which induces its transport activity (PubMed:26979622). {ECO:0000269|PubMed:11901164, ECO:0000269|PubMed:18479465, ECO:0000269|PubMed:19276087, ECO:0000269|PubMed:21566460, ECO:0000269|PubMed:21713032, ECO:0000269|PubMed:26979622}. |
| P07948 | LYN | Y194 | ochoa | Tyrosine-protein kinase Lyn (EC 2.7.10.2) (Lck/Yes-related novel protein tyrosine kinase) (V-yes-1 Yamaguchi sarcoma viral related oncogene homolog) (p53Lyn) (p56Lyn) | Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending on the context. Required for the initiation of the B-cell response, but also for its down-regulation and termination. Plays an important role in the regulation of B-cell differentiation, proliferation, survival and apoptosis, and is important for immune self-tolerance. Acts downstream of several immune receptors, including the B-cell receptor, CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4. Plays a role in the inflammatory response to bacterial lipopolysaccharide. Mediates the responses to cytokines and growth factors in hematopoietic progenitors, platelets, erythrocytes, and in mature myeloid cells, such as dendritic cells, neutrophils and eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an important role in integrin signaling. Regulates cell proliferation, survival, differentiation, migration, adhesion, degranulation, and cytokine release. Involved in the regulation of endothelial activation, neutrophil adhesion and transendothelial migration (PubMed:36932076). Down-regulates signaling pathways by phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIM), that then serve as binding sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1, that modulate signaling by dephosphorylation of kinases and their substrates. Phosphorylates LIME1 in response to CD22 activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A, CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B, SYK and TEC. Promotes phosphorylation of SIRPA, PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates phosphorylation of the BCR-ABL fusion protein. Required for rapid phosphorylation of FER in response to FCER1 activation. Mediates KIT phosphorylation. Acts as an effector of EPOR (erythropoietin receptor) in controlling KIT expression and may play a role in erythroid differentiation during the switch between proliferation and maturation. Depending on the context, activates or inhibits several signaling cascades. Regulates phosphatidylinositol 3-kinase activity and AKT1 activation. Regulates activation of the MAP kinase signaling cascade, including activation of MAP2K1/MEK1, MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates activation of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-72'. Kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation. Phosphorylates SCIMP on 'Tyr-107'; this enhances binding of SCIMP to TLR4, promoting the phosphorylation of TLR4, and a selective cytokine response to lipopolysaccharide in macrophages (By similarity). Phosphorylates CLNK (By similarity). Phosphorylates BCAR1/CAS and NEDD9/HEF1 (PubMed:9020138). {ECO:0000250|UniProtKB:P25911, ECO:0000269|PubMed:10574931, ECO:0000269|PubMed:10748115, ECO:0000269|PubMed:10891478, ECO:0000269|PubMed:11435302, ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:11825908, ECO:0000269|PubMed:14726379, ECO:0000269|PubMed:15795233, ECO:0000269|PubMed:16467205, ECO:0000269|PubMed:17640867, ECO:0000269|PubMed:17977829, ECO:0000269|PubMed:18056483, ECO:0000269|PubMed:18070987, ECO:0000269|PubMed:18235045, ECO:0000269|PubMed:18577747, ECO:0000269|PubMed:18802065, ECO:0000269|PubMed:19290919, ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:36122175, ECO:0000269|PubMed:36932076, ECO:0000269|PubMed:7687428, ECO:0000269|PubMed:9020138}. |
| P08631 | HCK | Y209 | ochoa|psp | Tyrosine-protein kinase HCK (EC 2.7.10.2) (Hematopoietic cell kinase) (Hemopoietic cell kinase) (p59-HCK/p60-HCK) (p59Hck) (p61Hck) | Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, including neutrophil, monocyte, macrophage and mast cell functions, phagocytosis, cell survival and proliferation, cell adhesion and migration. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as FCGR1A and FCGR2A, but also CSF3R, PLAUR, the receptors for IFNG, IL2, IL6 and IL8, and integrins, such as ITGB1 and ITGB2. During the phagocytic process, mediates mobilization of secretory lysosomes, degranulation, and activation of NADPH oxidase to bring about the respiratory burst. Plays a role in the release of inflammatory molecules. Promotes reorganization of the actin cytoskeleton and actin polymerization, formation of podosomes and cell protrusions. Inhibits TP73-mediated transcription activation and TP73-mediated apoptosis. Phosphorylates CBL in response to activation of immunoglobulin gamma Fc region receptors. Phosphorylates ADAM15, BCR, ELMO1, FCGR2A, GAB1, GAB2, RAPGEF1, STAT5B, TP73, VAV1 and WAS. {ECO:0000269|PubMed:10092522, ECO:0000269|PubMed:10779760, ECO:0000269|PubMed:10973280, ECO:0000269|PubMed:11741929, ECO:0000269|PubMed:11896602, ECO:0000269|PubMed:12411494, ECO:0000269|PubMed:15010462, ECO:0000269|PubMed:15952790, ECO:0000269|PubMed:15998323, ECO:0000269|PubMed:17310994, ECO:0000269|PubMed:17535448, ECO:0000269|PubMed:19114024, ECO:0000269|PubMed:19903482, ECO:0000269|PubMed:20452982, ECO:0000269|PubMed:21338576, ECO:0000269|PubMed:7535819, ECO:0000269|PubMed:8132624, ECO:0000269|PubMed:9406996, ECO:0000269|PubMed:9407116}. |
| P09769 | FGR | Y209 | ochoa | Tyrosine-protein kinase Fgr (EC 2.7.10.2) (Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog) (Proto-oncogene c-Fgr) (p55-Fgr) (p58-Fgr) (p58c-Fgr) | Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration. Promotes mast cell degranulation, release of inflammatory cytokines and IgE-mediated anaphylaxis. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as MS4A2/FCER1B, FCGR2A and/or FCGR2B. Acts downstream of ITGB1 and ITGB2, and regulates actin cytoskeleton reorganization, cell spreading and adhesion. Depending on the context, activates or inhibits cellular responses. Functions as a negative regulator of ITGB2 signaling, phagocytosis and SYK activity in monocytes. Required for normal ITGB1 and ITGB2 signaling, normal cell spreading and adhesion in neutrophils and macrophages. Functions as a positive regulator of cell migration and regulates cytoskeleton reorganization via RAC1 activation. Phosphorylates SYK (in vitro) and promotes SYK-dependent activation of AKT1 and MAP kinase signaling. Phosphorylates PLD2 in antigen-stimulated mast cells, leading to PLD2 activation and the production of the signaling molecules lysophosphatidic acid and diacylglycerol. Promotes activation of PIK3R1. Phosphorylates FASLG, and thereby regulates its ubiquitination and subsequent internalization. Phosphorylates ABL1. Promotes phosphorylation of CBL, CTTN, PIK3R1, PTK2/FAK1, PTK2B/PYK2 and VAV2. Phosphorylates HCLS1 that has already been phosphorylated by SYK, but not unphosphorylated HCLS1. Together with CLNK, it acts as a negative regulator of natural killer cell-activating receptors and inhibits interferon-gamma production (By similarity). {ECO:0000250|UniProtKB:P14234, ECO:0000269|PubMed:10739672, ECO:0000269|PubMed:17164290, ECO:0000269|PubMed:1737799, ECO:0000269|PubMed:7519620}. |
| P0CG38 | POTEI | Y791 | ochoa | POTE ankyrin domain family member I | None |
| P0CG39 | POTEJ | Y754 | ochoa | POTE ankyrin domain family member J | None |
| P11511 | CYP19A1 | Y361 | psp | Aromatase (EC 1.14.14.14) (CYPXIX) (Cytochrome P-450AROM) (Cytochrome P450 19A1) (Estrogen synthase) | A cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens, androst-4-ene-3,17-dione (androstenedione) and testosterone to the C18 estrogens, estrone and estradiol, respectively (PubMed:27702664, PubMed:2848247). Catalyzes three successive oxidations of C19 androgens: two conventional oxidations at C19 yielding 19-hydroxy and 19-oxo/19-aldehyde derivatives, followed by a third oxidative aromatization step that involves C1-beta hydrogen abstraction combined with cleavage of the C10-C19 bond to yield a phenolic A ring and formic acid (PubMed:20385561). Alternatively, the third oxidative reaction yields a 19-norsteroid and formic acid. Converts dihydrotestosterone to delta1,10-dehydro 19-nordihydrotestosterone and may play a role in homeostasis of this potent androgen (PubMed:22773874). Also displays 2-hydroxylase activity toward estrone (PubMed:22773874). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:20385561, PubMed:22773874). {ECO:0000269|PubMed:20385561, ECO:0000269|PubMed:22773874, ECO:0000269|PubMed:27702664, ECO:0000269|PubMed:2848247}. |
| P12277 | CKB | Y39 | ochoa | Creatine kinase B-type (EC 2.7.3.2) (Brain creatine kinase) (B-CK) (Creatine kinase B chain) (Creatine phosphokinase B-type) (CPK-B) | Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate) (PubMed:8186255). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa (Probable). Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle: localizes to the mitochondria of thermogenic fat cells and acts by mediating phosphorylation of creatine to initiate a futile cycle of creatine phosphorylation and dephosphorylation (By similarity). During the futile creatine cycle, creatine and N-phosphocreatine are in a futile cycle, which dissipates the high energy charge of N-phosphocreatine as heat without performing any mechanical or chemical work (By similarity). {ECO:0000250|UniProtKB:Q04447, ECO:0000269|PubMed:8186255, ECO:0000305}. |
| P12931 | SRC | Y216 | psp | Proto-oncogene tyrosine-protein kinase Src (EC 2.7.10.2) (Proto-oncogene c-Src) (pp60c-src) (p60-Src) | Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors (PubMed:34234773). Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN) (Probable). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN) (PubMed:21411625). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1 (Probable). Phosphorylates PKP3 at 'Tyr-195' in response to reactive oxygen species, which may cause the release of PKP3 from desmosome cell junctions into the cytoplasm (PubMed:25501895). Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors (By similarity). Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1 (PubMed:11389730). Plays a role in EGF-mediated calcium-activated chloride channel activation (PubMed:18586953). Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of GRK2, leading to beta-arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor (Probable). Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus (PubMed:7853507). Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function (PubMed:14585963, PubMed:8755529). Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase (PubMed:12615910). Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation (PubMed:16186108). Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731' (PubMed:20100835, PubMed:21309750). Enhances RIGI-elicited antiviral signaling (PubMed:19419966). Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376' (PubMed:14585963). Phosphorylates BCAR1 at 'Tyr-128' (PubMed:22710723). Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3 activity (PubMed:20525694). Phosphorylates synaptic vesicle protein synaptophysin (SYP) (By similarity). Involved in anchorage-independent cell growth (PubMed:19307596). Required for podosome formation (By similarity). Mediates IL6 signaling by activating YAP1-NOTCH pathway to induce inflammation-induced epithelial regeneration (PubMed:25731159). Phosphorylates OTUB1, promoting deubiquitination of RPTOR (PubMed:35927303). Phosphorylates caspase CASP8 at 'Tyr-380' which negatively regulates CASP8 processing and activation, down-regulating CASP8 proapoptotic function (PubMed:16619028). {ECO:0000250|UniProtKB:P05480, ECO:0000250|UniProtKB:Q9WUD9, ECO:0000269|PubMed:11389730, ECO:0000269|PubMed:12615910, ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:16186108, ECO:0000269|PubMed:16619028, ECO:0000269|PubMed:18586953, ECO:0000269|PubMed:19307596, ECO:0000269|PubMed:19419966, ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:21309750, ECO:0000269|PubMed:21411625, ECO:0000269|PubMed:22710723, ECO:0000269|PubMed:25501895, ECO:0000269|PubMed:25731159, ECO:0000269|PubMed:34234773, ECO:0000269|PubMed:35927303, ECO:0000269|PubMed:7853507, ECO:0000269|PubMed:8755529, ECO:0000269|PubMed:8759729, ECO:0000305|PubMed:11964124, ECO:0000305|PubMed:8672527, ECO:0000305|PubMed:9442882}.; FUNCTION: [Isoform 1]: Non-receptor protein tyrosine kinase which phosphorylates synaptophysin with high affinity. {ECO:0000250|UniProtKB:Q9WUD9}.; FUNCTION: [Isoform 2]: Non-receptor protein tyrosine kinase which shows higher basal kinase activity than isoform 1, possibly due to weakened intramolecular interactions which enhance autophosphorylation of Tyr-419 and subsequent activation (By similarity). The SH3 domain shows reduced affinity with the linker sequence between the SH2 and kinase domains which may account for the increased basal activity (By similarity). Displays altered substrate specificity compared to isoform 1, showing weak affinity for synaptophysin and for peptide substrates containing class I or class II SH3 domain-binding motifs (By similarity). Plays a role in L1CAM-mediated neurite elongation, possibly by acting downstream of L1CAM to drive cytoskeletal rearrangements involved in neurite outgrowth (By similarity). {ECO:0000250|UniProtKB:Q9WUD9}.; FUNCTION: [Isoform 3]: Non-receptor protein tyrosine kinase which shows higher basal kinase activity than isoform 1, possibly due to weakened intramolecular interactions which enhance autophosphorylation of Tyr-419 and subsequent activation (By similarity). The SH3 domain shows reduced affinity with the linker sequence between the SH2 and kinase domains which may account for the increased basal activity (By similarity). Displays altered substrate specificity compared to isoform 1, showing weak affinity for synaptophysin and for peptide substrates containing class I or class II SH3 domain-binding motifs (By similarity). Plays a role in neurite elongation (By similarity). {ECO:0000250|UniProtKB:Q9WUD9}. |
| P20963 | CD247 | Y142 | ochoa|psp | T-cell surface glycoprotein CD3 zeta chain (T-cell receptor T3 zeta chain) (CD antigen CD247) | Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways (PubMed:1384049, PubMed:1385158, PubMed:2470098, PubMed:7509083). CD3Z ITAMs phosphorylation creates multiple docking sites for the protein kinase ZAP70 leading to ZAP70 phosphorylation and its conversion into a catalytically active enzyme (PubMed:7509083). Plays an important role in intrathymic T-cell differentiation. Additionally, participates in the activity-dependent synapse formation of retinal ganglion cells (RGCs) in both the retina and dorsal lateral geniculate nucleus (dLGN) (By similarity). {ECO:0000250|UniProtKB:P24161, ECO:0000269|PubMed:1384049, ECO:0000269|PubMed:1385158, ECO:0000269|PubMed:16027224, ECO:0000269|PubMed:2470098, ECO:0000269|PubMed:28465009, ECO:0000269|PubMed:7509083}. |
| P31949 | S100A11 | Y30 | ochoa | Protein S100-A11 (Calgizzarin) (Metastatic lymph node gene 70 protein) (MLN 70) (Protein S100-C) (S100 calcium-binding protein A11) [Cleaved into: Protein S100-A11, N-terminally processed] | Facilitates the differentiation and the cornification of keratinocytes. {ECO:0000269|PubMed:18618420}. |
| P32004 | L1CAM | Y1176 | psp | Neural cell adhesion molecule L1 (N-CAM-L1) (NCAM-L1) (CD antigen CD171) | Neural cell adhesion molecule involved in the dynamics of cell adhesion and in the generation of transmembrane signals at tyrosine kinase receptors. During brain development, critical in multiple processes, including neuronal migration, axonal growth and fasciculation, and synaptogenesis. In the mature brain, plays a role in the dynamics of neuronal structure and function, including synaptic plasticity. {ECO:0000269|PubMed:20621658, ECO:0000305}. |
| P38919 | EIF4A3 | Y202 | ochoa | Eukaryotic initiation factor 4A-III (eIF-4A-III) (eIF4A-III) (EC 3.6.4.13) (ATP-dependent RNA helicase DDX48) (ATP-dependent RNA helicase eIF4A-3) (DEAD box protein 48) (Eukaryotic initiation factor 4A-like NUK-34) (Eukaryotic translation initiation factor 4A isoform 3) (Nuclear matrix protein 265) (NMP 265) (hNMP 265) [Cleaved into: Eukaryotic initiation factor 4A-III, N-terminally processed] | ATP-dependent RNA helicase (PubMed:16170325). Involved in pre-mRNA splicing as component of the spliceosome (PubMed:11991638, PubMed:22961380, PubMed:28076346, PubMed:28502770, PubMed:29301961). Core component of the splicing-dependent multiprotein exon junction complex (EJC) deposited at splice junctions on mRNAs (PubMed:16170325, PubMed:16209946, PubMed:16314458, PubMed:16923391, PubMed:16931718, PubMed:19033377, PubMed:20479275). The EJC is a dynamic structure consisting of core proteins and several peripheral nuclear and cytoplasmic associated factors that join the complex only transiently either during EJC assembly or during subsequent mRNA metabolism. The EJC marks the position of the exon-exon junction in the mature mRNA for the gene expression machinery and the core components remain bound to spliced mRNAs throughout all stages of mRNA metabolism thereby influencing downstream processes including nuclear mRNA export, subcellular mRNA localization, translation efficiency and nonsense-mediated mRNA decay (NMD). Its RNA-dependent ATPase and RNA-helicase activities are induced by CASC3, but abolished in presence of the MAGOH-RBM8A heterodimer, thereby trapping the ATP-bound EJC core onto spliced mRNA in a stable conformation. The inhibition of ATPase activity by the MAGOH-RBM8A heterodimer increases the RNA-binding affinity of the EJC. Involved in translational enhancement of spliced mRNAs after formation of the 80S ribosome complex. Binds spliced mRNA in sequence-independent manner, 20-24 nucleotides upstream of mRNA exon-exon junctions. Shows higher affinity for single-stranded RNA in an ATP-bound core EJC complex than after the ATP is hydrolyzed. Involved in the splicing modulation of BCL2L1/Bcl-X (and probably other apoptotic genes); specifically inhibits formation of proapoptotic isoforms such as Bcl-X(S); the function is different from the established EJC assembly (PubMed:22203037). Involved in craniofacial development (PubMed:24360810). {ECO:0000269|PubMed:11991638, ECO:0000269|PubMed:15034551, ECO:0000269|PubMed:16170325, ECO:0000269|PubMed:16209946, ECO:0000269|PubMed:16314458, ECO:0000269|PubMed:16923391, ECO:0000269|PubMed:16931718, ECO:0000269|PubMed:17375189, ECO:0000269|PubMed:19033377, ECO:0000269|PubMed:19409878, ECO:0000269|PubMed:20479275, ECO:0000269|PubMed:22203037, ECO:0000269|PubMed:22961380, ECO:0000269|PubMed:24360810, ECO:0000269|PubMed:28076346, ECO:0000269|PubMed:28502770, ECO:0000269|PubMed:29301961}. |
| P46531 | NOTCH1 | Y2323 | ochoa | Neurogenic locus notch homolog protein 1 (Notch 1) (hN1) (Translocation-associated notch protein TAN-1) [Cleaved into: Notch 1 extracellular truncation (NEXT); Notch 1 intracellular domain (NICD)] | Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Involved in the maturation of both CD4(+) and CD8(+) cells in the thymus. Important for follicular differentiation and possibly cell fate selection within the follicle. During cerebellar development, functions as a receptor for neuronal DNER and is involved in the differentiation of Bergmann glia. Represses neuronal and myogenic differentiation. May play an essential role in postimplantation development, probably in some aspect of cell specification and/or differentiation. May be involved in mesoderm development, somite formation and neurogenesis. May enhance HIF1A function by sequestering HIF1AN away from HIF1A. Required for the THBS4 function in regulating protective astrogenesis from the subventricular zone (SVZ) niche after injury. Involved in determination of left/right symmetry by modulating the balance between motile and immotile (sensory) cilia at the left-right organiser (LRO). {ECO:0000269|PubMed:20616313}. |
| P49448 | GLUD2 | Y451 | ochoa | Glutamate dehydrogenase 2, mitochondrial (GDH 2) (EC 1.4.1.3) | Important for recycling the chief excitatory neurotransmitter, glutamate, during neurotransmission. |
| P51451 | BLK | Y188 | ochoa | Tyrosine-protein kinase Blk (EC 2.7.10.2) (B lymphocyte kinase) (p55-Blk) | Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling (By similarity). B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors (By similarity). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (By similarity). Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor (By similarity). Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207' (By similarity). Also phosphorylates the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C (PubMed:8756631). With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation (By similarity). Also contributes to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation (By similarity). In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose (PubMed:19667185). Phosphorylates CGAS, promoting retention of CGAS in the cytosol (PubMed:30356214). {ECO:0000250|UniProtKB:P16277, ECO:0000269|PubMed:19667185, ECO:0000269|PubMed:30356214, ECO:0000269|PubMed:8756631}. |
| P60709 | ACTB | Y91 | ochoa | Actin, cytoplasmic 1 (EC 3.6.4.-) (Beta-actin) [Cleaved into: Actin, cytoplasmic 1, N-terminally processed] | Actin is a highly conserved protein that polymerizes to produce filaments that form cross-linked networks in the cytoplasm of cells (PubMed:25255767, PubMed:29581253). Actin exists in both monomeric (G-actin) and polymeric (F-actin) forms, both forms playing key functions, such as cell motility and contraction (PubMed:29581253). In addition to their role in the cytoplasmic cytoskeleton, G- and F-actin also localize in the nucleus, and regulate gene transcription and motility and repair of damaged DNA (PubMed:29925947). Plays a role in the assembly of the gamma-tubulin ring complex (gTuRC), which regulates the minus-end nucleation of alpha-beta tubulin heterodimers that grow into microtubule protafilaments (PubMed:39321809, PubMed:38609661). Part of the ACTR1A/ACTB filament around which the dynactin complex is built (By similarity). The dynactin multiprotein complex activates the molecular motor dynein for ultra-processive transport along microtubules (By similarity). {ECO:0000250|UniProtKB:Q6QAQ1, ECO:0000269|PubMed:25255767, ECO:0000269|PubMed:29581253, ECO:0000269|PubMed:29925947, ECO:0000269|PubMed:38609661, ECO:0000269|PubMed:39321809}. |
| P62805 | H4C1 | Y52 | ochoa | Histone H4 | Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. |
| P63261 | ACTG1 | Y91 | ochoa | Actin, cytoplasmic 2 (EC 3.6.4.-) (Gamma-actin) [Cleaved into: Actin, cytoplasmic 2, N-terminally processed] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. May play a role in the repair of noise-induced stereocilia gaps thereby maintains hearing sensitivity following loud noise damage (By similarity). {ECO:0000250|UniProtKB:P63260, ECO:0000305|PubMed:29581253}. |
| P68032 | ACTC1 | Y93 | ochoa | Actin, alpha cardiac muscle 1 (EC 3.6.4.-) (Alpha-cardiac actin) [Cleaved into: Actin, alpha cardiac muscle 1, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
| P68133 | ACTA1 | Y93 | ochoa | Actin, alpha skeletal muscle (EC 3.6.4.-) (Alpha-actin-1) [Cleaved into: Actin, alpha skeletal muscle, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
| Q02763 | TEK | Y897 | ochoa|psp | Angiopoietin-1 receptor (EC 2.7.10.1) (Endothelial tyrosine kinase) (Tunica interna endothelial cell kinase) (Tyrosine kinase with Ig and EGF homology domains-2) (Tyrosine-protein kinase receptor TEK) (Tyrosine-protein kinase receptor TIE-2) (hTIE2) (p140 TEK) (CD antigen CD202b) | Tyrosine-protein kinase that acts as a cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of pro-inflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1. {ECO:0000269|PubMed:12816861, ECO:0000269|PubMed:14665640, ECO:0000269|PubMed:15284220, ECO:0000269|PubMed:15851516, ECO:0000269|PubMed:18366015, ECO:0000269|PubMed:18425119, ECO:0000269|PubMed:18425120, ECO:0000269|PubMed:19223473, ECO:0000269|PubMed:20651738, ECO:0000269|PubMed:9204896}. |
| Q02790 | FKBP4 | Y220 | ochoa | Peptidyl-prolyl cis-trans isomerase FKBP4 (PPIase FKBP4) (EC 5.2.1.8) (51 kDa FK506-binding protein) (FKBP51) (52 kDa FK506-binding protein) (52 kDa FKBP) (FKBP-52) (59 kDa immunophilin) (p59) (FK506-binding protein 4) (FKBP-4) (FKBP59) (HSP-binding immunophilin) (HBI) (Immunophilin FKBP52) (Rotamase) [Cleaved into: Peptidyl-prolyl cis-trans isomerase FKBP4, N-terminally processed] | Immunophilin protein with PPIase and co-chaperone activities. Component of steroid receptors heterocomplexes through interaction with heat-shock protein 90 (HSP90). May play a role in the intracellular trafficking of heterooligomeric forms of steroid hormone receptors between cytoplasm and nuclear compartments. The isomerase activity controls neuronal growth cones via regulation of TRPC1 channel opening. Also acts as a regulator of microtubule dynamics by inhibiting MAPT/TAU ability to promote microtubule assembly. May have a protective role against oxidative stress in mitochondria. {ECO:0000269|PubMed:1279700, ECO:0000269|PubMed:1376003, ECO:0000269|PubMed:19945390, ECO:0000269|PubMed:21730050, ECO:0000269|PubMed:2378870}. |
| Q13002 | GRIK2 | Y590 | psp | Glutamate receptor ionotropic, kainate 2 (GluK2) (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6) | Ionotropic glutamate receptor that functions as a cation permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist (PubMed:14511640, PubMed:28180184, PubMed:34375587, PubMed:7536611, PubMed:8730589). Modulates cell surface expression of NETO2. In association with GRIK3, involved in presynaptic facilitation of glutamate release at hippocampal mossy fiber synapses (By similarity). {ECO:0000250|UniProtKB:P39087, ECO:0000269|PubMed:14511640, ECO:0000269|PubMed:28180184, ECO:0000269|PubMed:34375587, ECO:0000269|PubMed:7536611, ECO:0000269|PubMed:8730589}.; FUNCTION: Independent of its ionotropic glutamate receptor activity, acts as a thermoreceptor conferring sensitivity to cold temperatures (PubMed:31474366). Functions in dorsal root ganglion neurons (By similarity). {ECO:0000250|UniProtKB:P39087, ECO:0000269|PubMed:31474366}. |
| Q13439 | GOLGA4 | Y2148 | ochoa | Golgin subfamily A member 4 (256 kDa golgin) (Golgin-245) (Protein 72.1) (Trans-Golgi p230) | Involved in vesicular trafficking at the Golgi apparatus level. May play a role in delivery of transport vesicles containing GPI-linked proteins from the trans-Golgi network through its interaction with MACF1. Involved in endosome-to-Golgi trafficking (PubMed:29084197). {ECO:0000269|PubMed:15265687, ECO:0000269|PubMed:29084197}. |
| Q6S8J3 | POTEE | Y791 | ochoa | POTE ankyrin domain family member E (ANKRD26-like family C member 1A) (Prostate, ovary, testis-expressed protein on chromosome 2) (POTE-2) | None |
| Q6ZRV2 | FAM83H | Y908 | ochoa | Protein FAM83H | May play a major role in the structural organization and calcification of developing enamel (PubMed:18252228). May play a role in keratin cytoskeleton disassembly by recruiting CSNK1A1 to keratin filaments. Thereby, it may regulate epithelial cell migration (PubMed:23902688). {ECO:0000269|PubMed:18252228, ECO:0000269|PubMed:23902688}. |
| Q8IUH5 | ZDHHC17 | Y70 | ochoa | Palmitoyltransferase ZDHHC17 (EC 2.3.1.225) (Acyltransferase ZDHHC17) (EC 2.3.1.-) (DHHC domain-containing cysteine-rich protein 17) (DHHC17) (Huntingtin yeast partner H) (Huntingtin-interacting protein 14) (HIP-14) (Huntingtin-interacting protein 3) (HIP-3) (Huntingtin-interacting protein H) (Putative MAPK-activating protein PM11) (Putative NF-kappa-B-activating protein 205) (Zinc finger DHHC domain-containing protein 17) | Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates and is involved in a variety of cellular processes (PubMed:15489887, PubMed:15603740, PubMed:24705354, PubMed:27911442, PubMed:28757145). Has no stringent fatty acid selectivity and in addition to palmitate can also transfer onto target proteins myristate from tetradecanoyl-CoA and stearate from octadecanoyl-CoA (By similarity). Palmitoyltransferase specific for a subset of neuronal proteins, including SNAP25, DLG4/PSD95, GAD2, SYT1 and HTT (PubMed:15489887, PubMed:15603740, PubMed:19139280, PubMed:28757145). Also palmitoylates neuronal protein GPM6A as well as SPRED1 and SPRED3 (PubMed:24705354). Could also play a role in axonogenesis through the regulation of NTRK1 and the downstream ERK1/ERK2 signaling cascade (By similarity). May be involved in the sorting or targeting of critical proteins involved in the initiating events of endocytosis at the plasma membrane (PubMed:12393793). May play a role in Mg(2+) transport (PubMed:18794299). Could also palmitoylate DNAJC5 and regulate its localization to the Golgi membrane (By similarity). Palmitoylates CASP6, thereby preventing its dimerization and subsequent activation (PubMed:27911442). {ECO:0000250|UniProtKB:Q80TN5, ECO:0000269|PubMed:12393793, ECO:0000269|PubMed:15489887, ECO:0000269|PubMed:15603740, ECO:0000269|PubMed:18794299, ECO:0000269|PubMed:19139280, ECO:0000269|PubMed:24705354, ECO:0000269|PubMed:27911442, ECO:0000269|PubMed:28757145}. |
| Q8ND30 | PPFIBP2 | Y516 | ochoa | Liprin-beta-2 (Protein tyrosine phosphatase receptor type f polypeptide-interacting protein-binding protein 2) (PTPRF-interacting protein-binding protein 2) | May regulate the disassembly of focal adhesions. Did not bind receptor-like tyrosine phosphatases type 2A. {ECO:0000269|PubMed:9624153}. |
| Q8WWI1 | LMO7 | Y186 | ochoa | LIM domain only protein 7 (LMO-7) (F-box only protein 20) (LOMP) | None |
| Q9BPW8 | NIPSNAP1 | Y148 | ochoa | Protein NipSnap homolog 1 (NipSnap1) | Protein involved in mitophagy by facilitating recruitment of the autophagy machinery required for clearance of damaged mitochondria (PubMed:30982665). Accumulates on the mitochondria surface in response to mitochondrial depolarization and acts as a 'eat me' signal by recruiting proteins involved in selective autophagy, such as autophagy receptors (CALCOCO2/NDP52, NBR1, SQSTM1/p62, TAX1BP1 and WDFY3/ALFY) and ATG8 family proteins (MAP1LC3A, MAP1LC3B, MAP1LC3C, GABARAP, GABARAPL1 and GABARAPL2) (PubMed:30982665). {ECO:0000269|PubMed:30982665}. |
| Q9BYX7 | POTEKP | Y91 | ochoa | Putative beta-actin-like protein 3 (Kappa-actin) (POTE ankyrin domain family member K) | None |
| Q9GZM5 | YIPF3 | Y154 | ochoa | Protein YIPF3 (Killer lineage protein 1) (Natural killer cell-specific antigen KLIP1) (YIP1 family member 3) [Cleaved into: Protein YIPF3, 36 kDa form III] | Involved in the maintenance of the Golgi structure. May play a role in hematopoiesis. {ECO:0000269|PubMed:12490290, ECO:0000269|PubMed:21757827}. |
| Q9H4E7 | DEF6 | Y210 | psp | Differentially expressed in FDCP 6 homolog (DEF-6) (IRF4-binding protein) | Phosphatidylinositol 3,4,5-trisphosphate-dependent guanine nucleotide exchange factor (GEF) which plays a role in the activation of Rho GTPases RAC1, RhoA and CDC42 (PubMed:12651066, PubMed:15023524). Can regulate cell morphology in cooperation with activated RAC1 (By similarity). Involved in immune homeostasis by ensuring proper trafficking and availability of T-cell regulator CTLA-4 at T-cell surface (PubMed:31308374). Plays a role in Th2 (T helper cells) development and/or activation, perhaps by interfering with ZAP70 signaling (By similarity). {ECO:0000250|UniProtKB:Q8C2K1, ECO:0000269|PubMed:12651066, ECO:0000269|PubMed:15023524, ECO:0000269|PubMed:31308374}. |
| Q9H4L7 | SMARCAD1 | Y91 | ochoa | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A containing DEAD/H box 1 (SMARCAD1) (EC 3.6.4.12) (ATP-dependent helicase 1) (hHEL1) | DNA helicase that possesses intrinsic ATP-dependent nucleosome-remodeling activity and is both required for DNA repair and heterochromatin organization. Promotes DNA end resection of double-strand breaks (DSBs) following DNA damage: probably acts by weakening histone DNA interactions in nucleosomes flanking DSBs. Required for the restoration of heterochromatin organization after replication. Acts at replication sites to facilitate the maintenance of heterochromatin by directing H3 and H4 histones deacetylation, H3 'Lys-9' trimethylation (H3K9me3) and restoration of silencing. {ECO:0000269|PubMed:21549307, ECO:0000269|PubMed:22960744}. |
| Q9H7M9 | VSIR | Y265 | ochoa | V-type immunoglobulin domain-containing suppressor of T-cell activation (Platelet receptor Gi24) (Stress-induced secreted protein-1) (Sisp-1) (V-set domain-containing immunoregulatory receptor) (V-set immunoregulatory receptor) | Immunoregulatory receptor which inhibits the T-cell response (PubMed:24691993). May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling (By similarity). May stimulate MMP14-mediated MMP2 activation (PubMed:20666777). {ECO:0000250|UniProtKB:Q9D659, ECO:0000269|PubMed:20666777, ECO:0000269|PubMed:24691993}. |
| Q9HAU0 | PLEKHA5 | Y590 | ochoa | Pleckstrin homology domain-containing family A member 5 (PH domain-containing family A member 5) (Phosphoinositol 3-phosphate-binding protein 2) (PEPP-2) | None |
| Q9P2J5 | LARS1 | Y939 | ochoa | Leucine--tRNA ligase, cytoplasmic (EC 6.1.1.4) (Leucyl-tRNA synthetase) (LeuRS) (cLRS) | Aminoacyl-tRNA synthetase that catalyzes the specific attachment of leucine to its cognate tRNA (tRNA(Leu)) (PubMed:25051973, PubMed:32232361). It performs tRNA aminoacylation in a two-step reaction: Leu is initially activated by ATP to form a leucyl-adenylate (Leu-AMP) intermediate; then the leucyl moiety is transferred to the acceptor 3' end of the tRNA to yield leucyl-tRNA (PubMed:25051973). To improve the fidelity of catalytic reactions, it is also able to hydrolyze misactivated aminoacyl-adenylate intermediates (pre-transfer editing) and mischarged aminoacyl-tRNAs (post-transfer editing) (PubMed:25051973). {ECO:0000269|PubMed:19426743, ECO:0000269|PubMed:25051973, ECO:0000269|PubMed:32232361}. |
| Q9UNK9 | ANGEL1 | Y472 | ochoa | Protein angel homolog 1 | None |
| P22090 | RPS4Y1 | T141 | Sugiyama | Small ribosomal subunit protein eS4, Y isoform 1 (40S ribosomal protein S4) | None |
| P62701 | RPS4X | T141 | Sugiyama | Small ribosomal subunit protein eS4, X isoform (40S ribosomal protein S4) (SCR10) (Single copy abundant mRNA protein) | Component of the small ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797). {ECO:0000269|PubMed:23636399, ECO:0000269|PubMed:34516797}. |
| Q8TD47 | RPS4Y2 | T141 | Sugiyama | Small ribosomal subunit protein eS4, Y isoform 2 (40S ribosomal protein S4, Y isoform 2) | None |
| P07900 | HSP90AA1 | Y465 | Sugiyama | Heat shock protein HSP 90-alpha (EC 3.6.4.10) (Heat shock 86 kDa) (HSP 86) (HSP86) (Heat shock protein family C member 1) (Lipopolysaccharide-associated protein 2) (LAP-2) (LPS-associated protein 2) (Renal carcinoma antigen NY-REN-38) | Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity which is essential for its chaperone activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:11274138, PubMed:12526792, PubMed:15577939, PubMed:15937123, PubMed:27353360, PubMed:29127155). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself (PubMed:29127155). Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:26991466, PubMed:27295069). Plays a critical role in mitochondrial import, delivers preproteins to the mitochondrial import receptor TOMM70 (PubMed:12526792). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels (PubMed:25973397). In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues (PubMed:25973397). Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment (PubMed:25973397). Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205). Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation (PubMed:24613385). Mediates the association of TOMM70 with IRF3 or TBK1 in mitochondrial outer membrane which promotes host antiviral response (PubMed:20628368, PubMed:25609812). {ECO:0000269|PubMed:11274138, ECO:0000269|PubMed:11276205, ECO:0000269|PubMed:12526792, ECO:0000269|PubMed:15577939, ECO:0000269|PubMed:15937123, ECO:0000269|PubMed:20628368, ECO:0000269|PubMed:24613385, ECO:0000269|PubMed:25609812, ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:29127155, ECO:0000303|PubMed:25973397, ECO:0000303|PubMed:26991466, ECO:0000303|PubMed:27295069}.; FUNCTION: (Microbial infection) Seems to interfere with N.meningitidis NadA-mediated invasion of human cells. Decreasing HSP90 levels increases adhesion and entry of E.coli expressing NadA into human Chang cells; increasing its levels leads to decreased adhesion and invasion. {ECO:0000305|PubMed:22066472}. |
| P08238 | HSP90AB1 | Y305 | Sugiyama | Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84) (Heat shock protein family C member 3) | Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:16478993, PubMed:19696785). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself. Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:26991466, PubMed:27295069). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels. They first alter the steady-state levels of certain transcription factors in response to various physiological cues. Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment. Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation (PubMed:24613385). Promotes cell differentiation by chaperoning BIRC2 and thereby protecting from auto-ubiquitination and degradation by the proteasomal machinery (PubMed:18239673). Main chaperone involved in the phosphorylation/activation of the STAT1 by chaperoning both JAK2 and PRKCE under heat shock and in turn, activates its own transcription (PubMed:20353823). Involved in the translocation into ERGIC (endoplasmic reticulum-Golgi intermediate compartment) of leaderless cargos (lacking the secretion signal sequence) such as the interleukin 1/IL-1; the translocation process is mediated by the cargo receptor TMED10 (PubMed:32272059). {ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:18239673, ECO:0000269|PubMed:19696785, ECO:0000269|PubMed:20353823, ECO:0000269|PubMed:24613385, ECO:0000269|PubMed:32272059, ECO:0000303|PubMed:25973397, ECO:0000303|PubMed:26991466, ECO:0000303|PubMed:27295069}.; FUNCTION: (Microbial infection) Binding to N.meningitidis NadA stimulates monocytes (PubMed:21949862). Seems to interfere with N.meningitidis NadA-mediated invasion of human cells (Probable). {ECO:0000269|PubMed:21949862, ECO:0000305|PubMed:22066472}. |
| P18124 | RPL7 | Y155 | Sugiyama | Large ribosomal subunit protein uL30 (60S ribosomal protein L7) | Component of the large ribosomal subunit (PubMed:12962325, PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:12962325, PubMed:23636399, PubMed:32669547). Binds to G-rich structures in 28S rRNA and in mRNAs (PubMed:12962325). Plays a regulatory role in the translation apparatus; inhibits cell-free translation of mRNAs (PubMed:12962325). {ECO:0000269|PubMed:23636399, ECO:0000269|PubMed:32669547, ECO:0000305|PubMed:12962325}. |
| P31327 | CPS1 | Y1450 | Sugiyama | Carbamoyl-phosphate synthase [ammonia], mitochondrial (EC 6.3.4.16) (Carbamoyl-phosphate synthetase I) (CPSase I) | Involved in the urea cycle of ureotelic animals where the enzyme plays an important role in removing excess ammonia from the cell. |
| P36578 | RPL4 | Y211 | Sugiyama | Large ribosomal subunit protein uL4 (60S ribosomal protein L1) (60S ribosomal protein L4) | Component of the large ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. {ECO:0000269|PubMed:23636399, ECO:0000269|PubMed:32669547}. |
| P49327 | FASN | Y277 | Sugiyama | Fatty acid synthase (EC 2.3.1.85) (Type I fatty acid synthase) [Includes: [Acyl-carrier-protein] S-acetyltransferase (EC 2.3.1.38); [Acyl-carrier-protein] S-malonyltransferase (EC 2.3.1.39); 3-oxoacyl-[acyl-carrier-protein] synthase (EC 2.3.1.41); 3-oxoacyl-[acyl-carrier-protein] reductase (EC 1.1.1.100); 3-hydroxyacyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59); Enoyl-[acyl-carrier-protein] reductase (EC 1.3.1.39); Acyl-[acyl-carrier-protein] hydrolase (EC 3.1.2.14)] | Fatty acid synthetase is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH. This multifunctional protein contains 7 catalytic activities and a site for the binding of the prosthetic group 4'-phosphopantetheine of the acyl carrier protein ([ACP]) domain. {ECO:0000269|PubMed:16215233, ECO:0000269|PubMed:16969344, ECO:0000269|PubMed:26851298, ECO:0000269|PubMed:7567999, ECO:0000269|PubMed:8962082, ECO:0000269|PubMed:9356448}.; FUNCTION: (Microbial infection) Fatty acid synthetase activity is required for SARS coronavirus-2/SARS-CoV-2 replication. {ECO:0000269|PubMed:34320401}. |
| P55884 | EIF3B | Y232 | Sugiyama | Eukaryotic translation initiation factor 3 subunit B (eIF3b) (Eukaryotic translation initiation factor 3 subunit 9) (Prt1 homolog) (hPrt1) (eIF-3-eta) (eIF3 p110) (eIF3 p116) | RNA-binding component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17581632, PubMed:25849773, PubMed:27462815, PubMed:9388245). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17581632, PubMed:9388245). The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773). {ECO:0000255|HAMAP-Rule:MF_03001, ECO:0000269|PubMed:17581632, ECO:0000269|PubMed:25849773, ECO:0000269|PubMed:27462815, ECO:0000269|PubMed:9388245}.; FUNCTION: (Microbial infection) In case of FCV infection, plays a role in the ribosomal termination-reinitiation event leading to the translation of VP2 (PubMed:18056426). {ECO:0000269|PubMed:18056426}. |
| Q8IWA5 | SLC44A2 | Y308 | Sugiyama | Choline transporter-like protein 2 (Solute carrier family 44 member 2) | [Isoform 1]: Choline/H+ antiporter, mainly in mitochodria (PubMed:10677542, PubMed:20665236, PubMed:23651124, PubMed:33789160). Also acts as a low-affinity ethanolamine/H+ antiporter, regulating the supply of extracellular ethanolamine (Etn) for the CDP-Etn pathway, redistribute intracellular Etn and balance the CDP-Cho and CDP-Etn arms of the Kennedy pathway (PubMed:33789160). {ECO:0000269|PubMed:10677542, ECO:0000269|PubMed:20665236, ECO:0000269|PubMed:23651124, ECO:0000269|PubMed:33789160}.; FUNCTION: [Isoform 3]: Does not exhibit choline transporter activity. {ECO:0000269|PubMed:10677542, ECO:0000269|PubMed:20665236}. |
| P29144 | TPP2 | Y1042 | Sugiyama | Tripeptidyl-peptidase 2 (TPP-2) (EC 3.4.14.10) (Tripeptidyl aminopeptidase) (Tripeptidyl-peptidase II) (TPP-II) | Cytosolic tripeptidyl-peptidase that releases N-terminal tripeptides from polypeptides and is a component of the proteolytic cascade acting downstream of the 26S proteasome in the ubiquitin-proteasome pathway (PubMed:25525876, PubMed:30533531). It plays an important role in intracellular amino acid homeostasis (PubMed:25525876). Stimulates adipogenesis (By similarity). {ECO:0000250|UniProtKB:Q64514, ECO:0000269|PubMed:25525876, ECO:0000269|PubMed:30533531}. |
| O75489 | NDUFS3 | Y207 | Sugiyama | NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial (EC 7.1.1.2) (Complex I-30kD) (CI-30kD) (NADH-ubiquinone oxidoreductase 30 kDa subunit) | Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:14729820, PubMed:30140060). Essential for the catalytic activity and assembly of complex I (PubMed:14729820, PubMed:24028823, PubMed:30140060). {ECO:0000269|PubMed:14729820, ECO:0000269|PubMed:24028823, ECO:0000269|PubMed:30140060}. |
| Q9H814 | PHAX | Y152 | Sugiyama | Phosphorylated adapter RNA export protein (RNA U small nuclear RNA export adapter protein) | A phosphoprotein adapter involved in the XPO1-mediated U snRNA export from the nucleus (PubMed:39011894). Bridge components required for U snRNA export, the cap binding complex (CBC)-bound snRNA on the one hand and the GTPase Ran in its active GTP-bound form together with the export receptor XPO1 on the other. Its phosphorylation in the nucleus is required for U snRNA export complex assembly and export, while its dephosphorylation in the cytoplasm causes export complex disassembly. It is recycled back to the nucleus via the importin alpha/beta heterodimeric import receptor. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Its compartmentalized phosphorylation cycle may also contribute to the directionality of export. Binds strongly to m7G-capped U1 and U5 small nuclear RNAs (snRNAs) in a sequence-unspecific manner and phosphorylation-independent manner (By similarity). Also plays a role in the biogenesis of U3 small nucleolar RNA (snoRNA). Involved in the U3 snoRNA transport from nucleoplasm to Cajal bodies. Binds strongly to m7G-capped U3, U8 and U13 precursor snoRNAs and weakly to trimethylated (TMG)-capped U3, U8 and U13 snoRNAs. Also binds to telomerase RNA. {ECO:0000250, ECO:0000269|PubMed:15574332, ECO:0000269|PubMed:15574333}. |
| P31153 | MAT2A | Y188 | Sugiyama | S-adenosylmethionine synthase isoform type-2 (AdoMet synthase 2) (EC 2.5.1.6) (Methionine adenosyltransferase 2) (MAT 2) (Methionine adenosyltransferase II) (MAT-II) | Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis of the triphosphate. {ECO:0000269|PubMed:10644686, ECO:0000269|PubMed:23189196, ECO:0000269|PubMed:25075345}. |
| P63010 | AP2B1 | Y874 | Sugiyama | AP-2 complex subunit beta (AP105B) (Adaptor protein complex AP-2 subunit beta) (Adaptor-related protein complex 2 subunit beta) (Beta-2-adaptin) (Beta-adaptin) (Clathrin assembly protein complex 2 beta large chain) (Plasma membrane adaptor HA2/AP2 adaptin beta subunit) | Component of the adaptor protein complex 2 (AP-2). Adaptor protein complexes function in protein transport via transport vesicles in different membrane traffic pathways. Adaptor protein complexes are vesicle coat components and appear to be involved in cargo selection and vesicle formation. AP-2 is involved in clathrin-dependent endocytosis in which cargo proteins are incorporated into vesicles surrounded by clathrin (clathrin-coated vesicles, CCVs) which are destined for fusion with the early endosome. The clathrin lattice serves as a mechanical scaffold but is itself unable to bind directly to membrane components. Clathrin-associated adaptor protein (AP) complexes which can bind directly to both the clathrin lattice and to the lipid and protein components of membranes are considered to be the major clathrin adaptors contributing the CCV formation. AP-2 also serves as a cargo receptor to selectively sort the membrane proteins involved in receptor-mediated endocytosis. AP-2 seems to play a role in the recycling of synaptic vesicle membranes from the presynaptic surface. AP-2 recognizes Y-X-X-[FILMV] (Y-X-X-Phi) and [ED]-X-X-X-L-[LI] endocytosis signal motifs within the cytosolic tails of transmembrane cargo molecules. AP-2 may also play a role in maintaining normal post-endocytic trafficking through the ARF6-regulated, non-clathrin pathway. During long-term potentiation in hippocampal neurons, AP-2 is responsible for the endocytosis of ADAM10 (PubMed:23676497). The AP-2 beta subunit acts via its C-terminal appendage domain as a scaffolding platform for endocytic accessory proteins; at least some clathrin-associated sorting proteins (CLASPs) are recognized by their [DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif. The AP-2 beta subunit binds to clathrin heavy chain, promoting clathrin lattice assembly; clathrin displaces at least some CLASPs from AP2B1 which probably then can be positioned for further coat assembly. {ECO:0000269|PubMed:14745134, ECO:0000269|PubMed:14985334, ECO:0000269|PubMed:15473838, ECO:0000269|PubMed:19033387, ECO:0000269|PubMed:23676497}. |
| O60264 | SMARCA5 | Y141 | Sugiyama | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 (SMARCA5) (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5) (EC 3.6.4.-) (Sucrose nonfermenting protein 2 homolog) (hSNF2H) | ATPase that possesses intrinsic ATP-dependent nucleosome-remodeling activity (PubMed:12972596, PubMed:28801535). Catalytic subunit of ISWI chromatin-remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair; this may require intact histone H4 tails (PubMed:10880450, PubMed:12198550, PubMed:12434153, PubMed:12972596, PubMed:23911928, PubMed:28801535). Within the ISWI chromatin-remodeling complexes, slides edge- and center-positioned histone octamers away from their original location on the DNA template (PubMed:28801535). Catalytic activity and histone octamer sliding propensity is regulated and determined by components of the ISWI chromatin-remodeling complexes (PubMed:28801535). The BAZ1A/ACF1-, BAZ1B/WSTF-, BAZ2A/TIP5- and BAZ2B-containing ISWI chromatin-remodeling complexes regulate the spacing of nucleosomes along the chromatin and have the ability to slide mononucleosomes to the center of a DNA template in an ATP-dependent manner (PubMed:14759371, PubMed:15543136, PubMed:28801535). The CECR2- and RSF1-containing ISWI chromatin-remodeling complexes do not have the ability to slide mononucleosomes to the center of a DNA template (PubMed:28801535). Binds to core histones together with RSF1, and is required for the assembly of regular nucleosome arrays by the RSF-5 ISWI chromatin-remodeling complex (PubMed:12972596). Involved in DNA replication and together with BAZ1A/ACF1 is required for replication of pericentric heterochromatin in S-phase (PubMed:12434153). Probably plays a role in repression of RNA polymerase I dependent transcription of the rDNA locus, through the recruitment of the SIN3/HDAC1 corepressor complex to the rDNA promoter (By similarity). Essential component of the WICH-5 ISWI chromatin-remodeling complex (also called the WICH complex), a chromatin-remodeling complex that mobilizes nucleosomes and reconfigures irregular chromatin to a regular nucleosomal array structure (PubMed:11980720, PubMed:15543136). The WICH-5 ISWI chromatin-remodeling complex regulates the transcription of various genes, has a role in RNA polymerase I transcription (By similarity). Within the B-WICH complex has a role in RNA polymerase III transcription (PubMed:16603771). Mediates the histone H2AX phosphorylation at 'Tyr-142', and is involved in the maintenance of chromatin structures during DNA replication processes (By similarity). Essential component of NoRC-5 ISWI chromatin-remodeling complex, a complex that mediates silencing of a fraction of rDNA by recruiting histone-modifying enzymes and DNA methyltransferases, leading to heterochromatin formation and transcriptional silencing (By similarity). {ECO:0000250|UniProtKB:Q91ZW3, ECO:0000269|PubMed:10880450, ECO:0000269|PubMed:11980720, ECO:0000269|PubMed:12198550, ECO:0000269|PubMed:12434153, ECO:0000269|PubMed:12972596, ECO:0000269|PubMed:14759371, ECO:0000269|PubMed:15543136, ECO:0000269|PubMed:16603771, ECO:0000269|PubMed:23911928, ECO:0000269|PubMed:28801535}. |
| Q8N7H5 | PAF1 | Y323 | Sugiyama | RNA polymerase II-associated factor 1 homolog (hPAF1) (Pancreatic differentiation protein 2) | Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the RNF20/40 E3 ubiquitin-protein ligase complex. Involved in polyadenylation of mRNA precursors. Has oncogenic activity in vivo and in vitro. {ECO:0000269|PubMed:16491129, ECO:0000269|PubMed:19410543, ECO:0000269|PubMed:19952111, ECO:0000269|PubMed:20178742, ECO:0000269|PubMed:20541477, ECO:0000269|PubMed:21329879, ECO:0000269|PubMed:22419161}. |
| P14625 | HSP90B1 | Y480 | Sugiyama | Endoplasmin (EC 3.6.4.-) (94 kDa glucose-regulated protein) (GRP-94) (Heat shock protein 90 kDa beta member 1) (Heat shock protein family C member 4) (Tumor rejection antigen 1) (gp96 homolog) | ATP-dependent chaperone involved in the processing of proteins in the endoplasmic reticulum, regulating their transport (PubMed:23572575, PubMed:39509507). Together with MESD, acts as a modulator of the Wnt pathway by promoting the folding of LRP6, a coreceptor of the canonical Wnt pathway (PubMed:23572575, PubMed:39509507). When associated with CNPY3, required for proper folding of Toll-like receptors (PubMed:11584270). Promotes folding and trafficking of TLR4 to the cell surface (PubMed:11584270). May participate in the unfolding of cytosolic leaderless cargos (lacking the secretion signal sequence) such as the interleukin 1/IL-1 to facilitate their translocation into the ERGIC (endoplasmic reticulum-Golgi intermediate compartment) and secretion; the translocation process is mediated by the cargo receptor TMED10 (PubMed:32272059). {ECO:0000269|PubMed:11584270, ECO:0000269|PubMed:23572575, ECO:0000269|PubMed:32272059, ECO:0000269|PubMed:39509507}. |
| Q58FF3 | HSP90B2P | Y137 | Sugiyama | Putative endoplasmin-like protein (Putative heat shock protein 90 kDa beta member 2) | Putative molecular chaperone. {ECO:0000250}. |
| P16234 | PDGFRA | Y613 | Sugiyama | Platelet-derived growth factor receptor alpha (PDGF-R-alpha) (PDGFR-alpha) (EC 2.7.10.1) (Alpha platelet-derived growth factor receptor) (Alpha-type platelet-derived growth factor receptor) (CD140 antigen-like family member A) (CD140a antigen) (Platelet-derived growth factor alpha receptor) (Platelet-derived growth factor receptor 2) (PDGFR-2) (CD antigen CD140a) | Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. {ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:10947961, ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:17087943, ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17141222, ECO:0000269|PubMed:20972453, ECO:0000269|PubMed:21224473, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664, ECO:0000269|PubMed:8760137, ECO:0000269|PubMed:8943348}. |
| P30520 | ADSS2 | Y239 | Sugiyama | Adenylosuccinate synthetase isozyme 2 (AMPSase 2) (AdSS 2) (EC 6.3.4.4) (Adenylosuccinate synthetase, acidic isozyme) (Adenylosuccinate synthetase, liver isozyme) (L-type adenylosuccinate synthetase) (IMP--aspartate ligase 2) | Plays an important role in the de novo pathway and in the salvage pathway of purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP. {ECO:0000250|UniProtKB:P46664}. |
| O94979 | SEC31A | Y489 | Sugiyama | Protein transport protein Sec31A (ABP125) (ABP130) (SEC31-like protein 1) (SEC31-related protein A) (Web1-like protein) | Component of the coat protein complex II (COPII) which promotes the formation of transport vesicles from the endoplasmic reticulum (ER) (PubMed:10788476). The coat has two main functions, the physical deformation of the endoplasmic reticulum membrane into vesicles and the selection of cargo molecules (By similarity). {ECO:0000250|UniProtKB:Q9Z2Q1, ECO:0000269|PubMed:10788476}. |
| P30291 | WEE1 | Y325 | Sugiyama | Wee1-like protein kinase (WEE1hu) (EC 2.7.10.2) (Wee1A kinase) | Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15' (PubMed:15070733, PubMed:7743995, PubMed:8348613, PubMed:8428596). Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase (PubMed:7743995, PubMed:8348613, PubMed:8428596). Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur (PubMed:7743995, PubMed:8348613, PubMed:8428596). Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated (PubMed:7743995). A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation (PubMed:7743995). {ECO:0000269|PubMed:15070733, ECO:0000269|PubMed:7743995, ECO:0000269|PubMed:8348613, ECO:0000269|PubMed:8428596}. |
| Q9NPF5 | DMAP1 | Y58 | Sugiyama | DNA methyltransferase 1-associated protein 1 (DNMAP1) (DNMT1-associated protein 1) | Involved in transcription repression and activation. Its interaction with HDAC2 may provide a mechanism for histone deacetylation in heterochromatin following replication of DNA at late firing origins. Can also repress transcription independently of histone deacetylase activity. May specifically potentiate DAXX-mediated repression of glucocorticoid receptor-dependent transcription. Component of the NuA4 histone acetyltransferase (HAT) complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. NuA4 may also play a direct role in DNA repair when recruited to sites of DNA damage. Participates in the nuclear localization of URI1 and increases its transcriptional corepressor activity. {ECO:0000269|PubMed:14665632, ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:14978102, ECO:0000269|PubMed:15367675}. |
| Q13085 | ACACA | Y306 | Sugiyama | Acetyl-CoA carboxylase 1 (ACC1) (EC 6.4.1.2) (Acetyl-Coenzyme A carboxylase alpha) (ACC-alpha) | Cytosolic enzyme that catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the first and rate-limiting step of de novo fatty acid biosynthesis (PubMed:20457939, PubMed:20952656, PubMed:29899443). This is a 2 steps reaction starting with the ATP-dependent carboxylation of the biotin carried by the biotin carboxyl carrier (BCC) domain followed by the transfer of the carboxyl group from carboxylated biotin to acetyl-CoA (PubMed:20457939, PubMed:20952656, PubMed:29899443). {ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656, ECO:0000269|PubMed:29899443}. |
| Q9HC38 | GLOD4 | Y192 | Sugiyama | Glyoxalase domain-containing protein 4 | None |
| Q04912 | MST1R | Y1097 | Sugiyama | Macrophage-stimulating protein receptor (MSP receptor) (EC 2.7.10.1) (CDw136) (Protein-tyrosine kinase 8) (p185-Ron) (CD antigen CD136) [Cleaved into: Macrophage-stimulating protein receptor alpha chain; Macrophage-stimulating protein receptor beta chain] | Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Also plays a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand. {ECO:0000269|PubMed:18836480, ECO:0000269|PubMed:7939629, ECO:0000269|PubMed:9764835}. |
| P84022 | SMAD3 | Y88 | Sugiyama | Mothers against decapentaplegic homolog 3 (MAD homolog 3) (Mad3) (Mothers against DPP homolog 3) (hMAD-3) (JV15-2) (SMAD family member 3) (SMAD 3) (Smad3) (hSMAD3) | Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. {ECO:0000269|PubMed:10995748, ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252, ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:16862174, ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:9732876, ECO:0000269|PubMed:9892009}. |
| Q15796 | SMAD2 | Y128 | Sugiyama | Mothers against decapentaplegic homolog 2 (MAD homolog 2) (Mothers against DPP homolog 2) (JV18-1) (Mad-related protein 2) (hMAD-2) (SMAD family member 2) (SMAD 2) (Smad2) (hSMAD2) | Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD2/SMAD4 complex, activates transcription. Promotes TGFB1-mediated transcription of odontoblastic differentiation genes in dental papilla cells (By similarity). Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. May act as a tumor suppressor in colorectal carcinoma (PubMed:8752209). {ECO:0000250|UniProtKB:Q62432, ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:16862174, ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:8752209, ECO:0000269|PubMed:9892009}. |
Download
| reactome_id | name | p | -log10_p |
|---|---|---|---|
| R-HSA-5663202 | Diseases of signal transduction by growth factor receptors and second messengers | 2.302867e-08 | 7.638 |
| R-HSA-422475 | Axon guidance | 8.975077e-09 | 8.047 |
| R-HSA-9675108 | Nervous system development | 2.443596e-08 | 7.612 |
| R-HSA-163765 | ChREBP activates metabolic gene expression | 5.382129e-08 | 7.269 |
| R-HSA-210990 | PECAM1 interactions | 5.382129e-08 | 7.269 |
| R-HSA-2029480 | Fcgamma receptor (FCGR) dependent phagocytosis | 9.568374e-08 | 7.019 |
| R-HSA-3928665 | EPH-ephrin mediated repulsion of cells | 1.191513e-07 | 6.924 |
| R-HSA-1433559 | Regulation of KIT signaling | 1.850726e-07 | 6.733 |
| R-HSA-164944 | Nef and signal transduction | 5.179617e-07 | 6.286 |
| R-HSA-389513 | Co-inhibition by CTLA4 | 9.212005e-07 | 6.036 |
| R-HSA-9670439 | Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT m... | 1.597538e-06 | 5.797 |
| R-HSA-9664422 | FCGR3A-mediated phagocytosis | 1.411583e-06 | 5.850 |
| R-HSA-9664417 | Leishmania phagocytosis | 1.411583e-06 | 5.850 |
| R-HSA-9664407 | Parasite infection | 1.411583e-06 | 5.850 |
| R-HSA-1433557 | Signaling by SCF-KIT | 1.545860e-06 | 5.811 |
| R-HSA-9669938 | Signaling by KIT in disease | 1.597538e-06 | 5.797 |
| R-HSA-3928662 | EPHB-mediated forward signaling | 1.727411e-06 | 5.763 |
| R-HSA-164952 | The role of Nef in HIV-1 replication and disease pathogenesis | 1.893741e-06 | 5.723 |
| R-HSA-9764561 | Regulation of CDH1 Function | 6.137881e-06 | 5.212 |
| R-HSA-2682334 | EPH-Ephrin signaling | 6.933611e-06 | 5.159 |
| R-HSA-2029481 | FCGR activation | 7.382802e-06 | 5.132 |
| R-HSA-9680350 | Signaling by CSF1 (M-CSF) in myeloid cells | 1.003006e-05 | 4.999 |
| R-HSA-9706374 | FLT3 signaling through SRC family kinases | 1.054296e-05 | 4.977 |
| R-HSA-912631 | Regulation of signaling by CBL | 2.422618e-05 | 4.616 |
| R-HSA-437239 | Recycling pathway of L1 | 4.042409e-05 | 4.393 |
| R-HSA-9658195 | Leishmania infection | 4.122354e-05 | 4.385 |
| R-HSA-9824443 | Parasitic Infection Pathways | 4.122354e-05 | 4.385 |
| R-HSA-389356 | Co-stimulation by CD28 | 4.399905e-05 | 4.357 |
| R-HSA-9664323 | FCGR3A-mediated IL10 synthesis | 5.393457e-05 | 4.268 |
| R-HSA-445095 | Interaction between L1 and Ankyrins | 8.264285e-05 | 4.083 |
| R-HSA-3928663 | EPHA-mediated growth cone collapse | 8.264285e-05 | 4.083 |
| R-HSA-72689 | Formation of a pool of free 40S subunits | 9.232185e-05 | 4.035 |
| R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | 1.017082e-04 | 3.993 |
| R-HSA-9913351 | Formation of the dystrophin-glycoprotein complex (DGC) | 1.279230e-04 | 3.893 |
| R-HSA-2426168 | Activation of gene expression by SREBF (SREBP) | 1.330371e-04 | 3.876 |
| R-HSA-72706 | GTP hydrolysis and joining of the 60S ribosomal subunit | 1.800859e-04 | 3.745 |
| R-HSA-156827 | L13a-mediated translational silencing of Ceruloplasmin expression | 1.800859e-04 | 3.745 |
| R-HSA-3304347 | Loss of Function of SMAD4 in Cancer | 2.015961e-04 | 3.696 |
| R-HSA-3311021 | SMAD4 MH2 Domain Mutants in Cancer | 2.015961e-04 | 3.696 |
| R-HSA-3315487 | SMAD2/3 MH2 Domain Mutants in Cancer | 2.015961e-04 | 3.696 |
| R-HSA-927802 | Nonsense-Mediated Decay (NMD) | 2.145252e-04 | 3.669 |
| R-HSA-975957 | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 2.145252e-04 | 3.669 |
| R-HSA-1266738 | Developmental Biology | 2.370242e-04 | 3.625 |
| R-HSA-373760 | L1CAM interactions | 2.757072e-04 | 3.560 |
| R-HSA-72613 | Eukaryotic Translation Initiation | 2.757072e-04 | 3.560 |
| R-HSA-72737 | Cap-dependent Translation Initiation | 2.757072e-04 | 3.560 |
| R-HSA-399954 | Sema3A PAK dependent Axon repulsion | 3.140469e-04 | 3.503 |
| R-HSA-3371568 | Attenuation phase | 3.162585e-04 | 3.500 |
| R-HSA-9662851 | Anti-inflammatory response favouring Leishmania parasite infection | 3.536256e-04 | 3.451 |
| R-HSA-9664433 | Leishmania parasite growth and survival | 3.536256e-04 | 3.451 |
| R-HSA-1655829 | Regulation of cholesterol biosynthesis by SREBP (SREBF) | 3.374433e-04 | 3.472 |
| R-HSA-9764265 | Regulation of CDH1 Expression and Function | 3.536256e-04 | 3.451 |
| R-HSA-9764274 | Regulation of Expression and Function of Type I Classical Cadherins | 3.536256e-04 | 3.451 |
| R-HSA-512988 | Interleukin-3, Interleukin-5 and GM-CSF signaling | 3.988333e-04 | 3.399 |
| R-HSA-1500931 | Cell-Cell communication | 4.898673e-04 | 3.310 |
| R-HSA-72695 | Formation of the ternary complex, and subsequently, the 43S complex | 5.315038e-04 | 3.274 |
| R-HSA-156902 | Peptide chain elongation | 5.512218e-04 | 3.259 |
| R-HSA-9954714 | PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | 6.317310e-04 | 3.199 |
| R-HSA-975956 | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 6.604315e-04 | 3.180 |
| R-HSA-9759476 | Regulation of Homotypic Cell-Cell Adhesion | 6.880840e-04 | 3.162 |
| R-HSA-156842 | Eukaryotic Translation Elongation | 6.900981e-04 | 3.161 |
| R-HSA-3371571 | HSF1-dependent transactivation | 7.381140e-04 | 3.132 |
| R-HSA-3656532 | TGFBR1 KD Mutants in Cancer | 7.957629e-04 | 3.099 |
| R-HSA-9954716 | ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ri... | 7.851004e-04 | 3.105 |
| R-HSA-72764 | Eukaryotic Translation Termination | 8.188384e-04 | 3.087 |
| R-HSA-376176 | Signaling by ROBO receptors | 8.286292e-04 | 3.082 |
| R-HSA-8953897 | Cellular responses to stimuli | 8.378810e-04 | 3.077 |
| R-HSA-72649 | Translation initiation complex formation | 8.862528e-04 | 3.052 |
| R-HSA-72702 | Ribosomal scanning and start codon recognition | 9.959323e-04 | 3.002 |
| R-HSA-2408557 | Selenocysteine synthesis | 1.044494e-03 | 2.981 |
| R-HSA-1643685 | Disease | 9.565473e-04 | 3.019 |
| R-HSA-5663205 | Infectious disease | 1.016690e-03 | 2.993 |
| R-HSA-3304356 | SMAD2/3 Phosphorylation Motif Mutants in Cancer | 1.078350e-03 | 2.967 |
| R-HSA-8939245 | RUNX1 regulates transcription of genes involved in BCR signaling | 1.078350e-03 | 2.967 |
| R-HSA-3656534 | Loss of Function of TGFBR1 in Cancer | 1.078350e-03 | 2.967 |
| R-HSA-192823 | Viral mRNA Translation | 1.129080e-03 | 2.947 |
| R-HSA-72662 | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and sub... | 1.114824e-03 | 2.953 |
| R-HSA-9633012 | Response of EIF2AK4 (GCN2) to amino acid deficiency | 1.173228e-03 | 2.931 |
| R-HSA-168273 | Influenza Viral RNA Transcription and Replication | 1.212800e-03 | 2.916 |
| R-HSA-9010553 | Regulation of expression of SLITs and ROBOs | 1.109838e-03 | 2.955 |
| R-HSA-418990 | Adherens junctions interactions | 1.235442e-03 | 2.908 |
| R-HSA-1227986 | Signaling by ERBB2 | 1.243337e-03 | 2.905 |
| R-HSA-1799339 | SRP-dependent cotranslational protein targeting to membrane | 1.362706e-03 | 2.866 |
| R-HSA-3304349 | Loss of Function of SMAD2/3 in Cancer | 1.402256e-03 | 2.853 |
| R-HSA-2408522 | Selenoamino acid metabolism | 1.565998e-03 | 2.805 |
| R-HSA-2262752 | Cellular responses to stress | 1.713750e-03 | 2.766 |
| R-HSA-3304351 | Signaling by TGF-beta Receptor Complex in Cancer | 1.766919e-03 | 2.753 |
| R-HSA-167590 | Nef Mediated CD4 Down-regulation | 2.171787e-03 | 2.663 |
| R-HSA-4420097 | VEGFA-VEGFR2 Pathway | 1.934514e-03 | 2.713 |
| R-HSA-202733 | Cell surface interactions at the vascular wall | 1.905963e-03 | 2.720 |
| R-HSA-5336415 | Uptake and function of diphtheria toxin | 2.171787e-03 | 2.663 |
| R-HSA-168255 | Influenza Infection | 2.381209e-03 | 2.623 |
| R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 2.505027e-03 | 2.601 |
| R-HSA-3000171 | Non-integrin membrane-ECM interactions | 2.554687e-03 | 2.593 |
| R-HSA-421270 | Cell-cell junction organization | 2.559159e-03 | 2.592 |
| R-HSA-162909 | Host Interactions of HIV factors | 2.584072e-03 | 2.588 |
| R-HSA-9032500 | Activated NTRK2 signals through FYN | 2.616309e-03 | 2.582 |
| R-HSA-196025 | Formation of annular gap junctions | 2.616309e-03 | 2.582 |
| R-HSA-9958517 | SLC-mediated bile acid transport | 2.616309e-03 | 2.582 |
| R-HSA-190873 | Gap junction degradation | 3.099942e-03 | 2.509 |
| R-HSA-194138 | Signaling by VEGF | 2.747576e-03 | 2.561 |
| R-HSA-9735869 | SARS-CoV-1 modulates host translation machinery | 2.833482e-03 | 2.548 |
| R-HSA-388841 | Regulation of T cell activation by CD28 family | 2.830095e-03 | 2.548 |
| R-HSA-9834752 | Respiratory syncytial virus genome replication | 3.099942e-03 | 2.509 |
| R-HSA-162582 | Signal Transduction | 2.948202e-03 | 2.530 |
| R-HSA-109582 | Hemostasis | 3.175330e-03 | 2.498 |
| R-HSA-199418 | Negative regulation of the PI3K/AKT network | 3.189007e-03 | 2.496 |
| R-HSA-3371511 | HSF1 activation | 3.236965e-03 | 2.490 |
| R-HSA-114604 | GPVI-mediated activation cascade | 3.236965e-03 | 2.490 |
| R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants | 3.451227e-03 | 2.462 |
| R-HSA-451308 | Activation of Ca-permeable Kainate Receptor | 3.622149e-03 | 2.441 |
| R-HSA-9820962 | Assembly and release of respiratory syncytial virus (RSV) virions | 3.622149e-03 | 2.441 |
| R-HSA-451306 | Ionotropic activity of kainate receptors | 4.182395e-03 | 2.379 |
| R-HSA-9948299 | Ribosome-associated quality control | 4.221912e-03 | 2.374 |
| R-HSA-9656223 | Signaling by RAF1 mutants | 4.651871e-03 | 2.332 |
| R-HSA-5674135 | MAP2K and MAPK activation | 4.651871e-03 | 2.332 |
| R-HSA-2029482 | Regulation of actin dynamics for phagocytic cup formation | 4.573543e-03 | 2.340 |
| R-HSA-168249 | Innate Immune System | 4.177124e-03 | 2.379 |
| R-HSA-9607240 | FLT3 Signaling | 4.394172e-03 | 2.357 |
| R-HSA-163685 | Integration of energy metabolism | 3.998511e-03 | 2.398 |
| R-HSA-446728 | Cell junction organization | 4.292901e-03 | 2.367 |
| R-HSA-9824446 | Viral Infection Pathways | 4.584391e-03 | 2.339 |
| R-HSA-449147 | Signaling by Interleukins | 4.475570e-03 | 2.349 |
| R-HSA-381183 | ATF6 (ATF6-alpha) activates chaperone genes | 4.780155e-03 | 2.321 |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation | 4.933388e-03 | 2.307 |
| R-HSA-8856828 | Clathrin-mediated endocytosis | 4.945569e-03 | 2.306 |
| R-HSA-5673001 | RAF/MAP kinase cascade | 5.210467e-03 | 2.283 |
| R-HSA-168256 | Immune System | 5.446528e-03 | 2.264 |
| R-HSA-9674415 | Drug resistance of PDGFR mutants | 6.746276e-03 | 2.171 |
| R-HSA-9674428 | PDGFR mutants bind TKIs | 6.746276e-03 | 2.171 |
| R-HSA-9674403 | Regorafenib-resistant PDGFR mutants | 6.746276e-03 | 2.171 |
| R-HSA-9674404 | Sorafenib-resistant PDGFR mutants | 6.746276e-03 | 2.171 |
| R-HSA-9674401 | Sunitinib-resistant PDGFR mutants | 6.746276e-03 | 2.171 |
| R-HSA-9674396 | Imatinib-resistant PDGFR mutants | 6.746276e-03 | 2.171 |
| R-HSA-389359 | CD28 dependent Vav1 pathway | 6.086128e-03 | 2.216 |
| R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF | 6.076601e-03 | 2.216 |
| R-HSA-9649948 | Signaling downstream of RAS mutants | 6.076601e-03 | 2.216 |
| R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants | 6.076601e-03 | 2.216 |
| R-HSA-6802949 | Signaling by RAS mutants | 6.076601e-03 | 2.216 |
| R-HSA-9796292 | Formation of axial mesoderm | 6.086128e-03 | 2.216 |
| R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer | 5.654370e-03 | 2.248 |
| R-HSA-75035 | Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 6.086128e-03 | 2.216 |
| R-HSA-157858 | Gap junction trafficking and regulation | 7.043295e-03 | 2.152 |
| R-HSA-9029558 | NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | 6.086128e-03 | 2.216 |
| R-HSA-75892 | Platelet Adhesion to exposed collagen | 6.086128e-03 | 2.216 |
| R-HSA-9818030 | NFE2L2 regulating tumorigenic genes | 6.086128e-03 | 2.216 |
| R-HSA-5684996 | MAPK1/MAPK3 signaling | 5.866754e-03 | 2.232 |
| R-HSA-381033 | ATF6 (ATF6-alpha) activates chaperones | 6.086128e-03 | 2.216 |
| R-HSA-9679191 | Potential therapeutics for SARS | 5.896443e-03 | 2.229 |
| R-HSA-9711097 | Cellular response to starvation | 7.133313e-03 | 2.147 |
| R-HSA-418885 | DCC mediated attractive signaling | 7.535954e-03 | 2.123 |
| R-HSA-1502540 | Signaling by Activin | 7.535954e-03 | 2.123 |
| R-HSA-196780 | Biotin transport and metabolism | 7.535954e-03 | 2.123 |
| R-HSA-446353 | Cell-extracellular matrix interactions | 7.535954e-03 | 2.123 |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression | 8.466666e-03 | 2.072 |
| R-HSA-9692914 | SARS-CoV-1-host interactions | 8.723791e-03 | 2.059 |
| R-HSA-9754678 | SARS-CoV-2 modulates host translation machinery | 8.846929e-03 | 2.053 |
| R-HSA-9725370 | Signaling by ALK fusions and activated point mutants | 8.977366e-03 | 2.047 |
| R-HSA-9700206 | Signaling by ALK in cancer | 8.977366e-03 | 2.047 |
| R-HSA-6791226 | Major pathway of rRNA processing in the nucleolus and cytosol | 9.513026e-03 | 2.022 |
| R-HSA-164938 | Nef-mediates down modulation of cell surface receptors by recruiting them to cla... | 9.971618e-03 | 2.001 |
| R-HSA-1912422 | Pre-NOTCH Expression and Processing | 1.060020e-02 | 1.975 |
| R-HSA-3928664 | Ephrin signaling | 1.085111e-02 | 1.965 |
| R-HSA-9613829 | Chaperone Mediated Autophagy | 1.085111e-02 | 1.965 |
| R-HSA-71291 | Metabolism of amino acids and derivatives | 1.162385e-02 | 1.935 |
| R-HSA-9754189 | Germ layer formation at gastrulation | 1.176361e-02 | 1.929 |
| R-HSA-375165 | NCAM signaling for neurite out-growth | 1.224875e-02 | 1.912 |
| R-HSA-5683057 | MAPK family signaling cascades | 1.266862e-02 | 1.897 |
| R-HSA-9823730 | Formation of definitive endoderm | 1.270862e-02 | 1.896 |
| R-HSA-1181150 | Signaling by NODAL | 1.270862e-02 | 1.896 |
| R-HSA-373755 | Semaphorin interactions | 1.271959e-02 | 1.896 |
| R-HSA-2219528 | PI3K/AKT Signaling in Cancer | 1.272006e-02 | 1.896 |
| R-HSA-202430 | Translocation of ZAP-70 to Immunological synapse | 1.790516e-02 | 1.747 |
| R-HSA-6802952 | Signaling by BRAF and RAF1 fusions | 1.369209e-02 | 1.864 |
| R-HSA-9671555 | Signaling by PDGFR in disease | 1.469433e-02 | 1.833 |
| R-HSA-3371497 | HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of lig... | 1.522830e-02 | 1.817 |
| R-HSA-5250913 | Positive epigenetic regulation of rRNA expression | 1.685805e-02 | 1.773 |
| R-HSA-9705462 | Inactivation of CSF3 (G-CSF) signaling | 1.469433e-02 | 1.833 |
| R-HSA-3371556 | Cellular response to heat stress | 1.370569e-02 | 1.863 |
| R-HSA-2173788 | Downregulation of TGF-beta receptor signaling | 1.573410e-02 | 1.803 |
| R-HSA-76002 | Platelet activation, signaling and aggregation | 1.523322e-02 | 1.817 |
| R-HSA-9617828 | FOXO-mediated transcription of cell cycle genes | 1.469433e-02 | 1.833 |
| R-HSA-9013695 | NOTCH4 Intracellular Domain Regulates Transcription | 1.368569e-02 | 1.864 |
| R-HSA-9006931 | Signaling by Nuclear Receptors | 1.565848e-02 | 1.805 |
| R-HSA-8868773 | rRNA processing in the nucleus and cytosol | 1.363976e-02 | 1.865 |
| R-HSA-5621575 | CD209 (DC-SIGN) signaling | 1.790516e-02 | 1.747 |
| R-HSA-1280215 | Cytokine Signaling in Immune system | 1.606943e-02 | 1.794 |
| R-HSA-9679506 | SARS-CoV Infections | 1.654743e-02 | 1.781 |
| R-HSA-69473 | G2/M DNA damage checkpoint | 1.858186e-02 | 1.731 |
| R-HSA-9022699 | MECP2 regulates neuronal receptors and channels | 2.019526e-02 | 1.695 |
| R-HSA-9018519 | Estrogen-dependent gene expression | 2.063747e-02 | 1.685 |
| R-HSA-6796648 | TP53 Regulates Transcription of DNA Repair Genes | 2.102720e-02 | 1.677 |
| R-HSA-202427 | Phosphorylation of CD3 and TCR zeta chains | 2.138385e-02 | 1.670 |
| R-HSA-389357 | CD28 dependent PI3K/Akt signaling | 2.138385e-02 | 1.670 |
| R-HSA-9006115 | Signaling by NTRK2 (TRKB) | 2.138385e-02 | 1.670 |
| R-HSA-381119 | Unfolded Protein Response (UPR) | 2.196806e-02 | 1.658 |
| R-HSA-451326 | Activation of kainate receptors upon glutamate binding | 2.260088e-02 | 1.646 |
| R-HSA-8940973 | RUNX2 regulates osteoblast differentiation | 2.260088e-02 | 1.646 |
| R-HSA-9674555 | Signaling by CSF3 (G-CSF) | 2.384592e-02 | 1.623 |
| R-HSA-5653656 | Vesicle-mediated transport | 2.505393e-02 | 1.601 |
| R-HSA-2424491 | DAP12 signaling | 2.511855e-02 | 1.600 |
| R-HSA-6802957 | Oncogenic MAPK signaling | 2.571155e-02 | 1.590 |
| R-HSA-186763 | Downstream signal transduction | 2.641834e-02 | 1.578 |
| R-HSA-9665230 | Drug resistance in ERBB2 KD mutants | 2.671571e-02 | 1.573 |
| R-HSA-9652282 | Drug-mediated inhibition of ERBB2 signaling | 2.671571e-02 | 1.573 |
| R-HSA-9665233 | Resistance of ERBB2 KD mutants to trastuzumab | 2.671571e-02 | 1.573 |
| R-HSA-9665245 | Resistance of ERBB2 KD mutants to tesevatinib | 2.671571e-02 | 1.573 |
| R-HSA-9665250 | Resistance of ERBB2 KD mutants to AEE788 | 2.671571e-02 | 1.573 |
| R-HSA-9665251 | Resistance of ERBB2 KD mutants to lapatinib | 2.671571e-02 | 1.573 |
| R-HSA-9665244 | Resistance of ERBB2 KD mutants to sapitinib | 2.671571e-02 | 1.573 |
| R-HSA-9665247 | Resistance of ERBB2 KD mutants to osimertinib | 2.671571e-02 | 1.573 |
| R-HSA-9665249 | Resistance of ERBB2 KD mutants to afatinib | 2.671571e-02 | 1.573 |
| R-HSA-9665737 | Drug resistance in ERBB2 TMD/JMD mutants | 2.671571e-02 | 1.573 |
| R-HSA-9665246 | Resistance of ERBB2 KD mutants to neratinib | 2.671571e-02 | 1.573 |
| R-HSA-162906 | HIV Infection | 2.676779e-02 | 1.572 |
| R-HSA-166520 | Signaling by NTRKs | 2.677726e-02 | 1.572 |
| R-HSA-9705683 | SARS-CoV-2-host interactions | 2.717208e-02 | 1.566 |
| R-HSA-9758941 | Gastrulation | 2.729018e-02 | 1.564 |
| R-HSA-2173795 | Downregulation of SMAD2/3:SMAD4 transcriptional activity | 2.774488e-02 | 1.557 |
| R-HSA-72312 | rRNA processing | 2.882822e-02 | 1.540 |
| R-HSA-354192 | Integrin signaling | 2.909775e-02 | 1.536 |
| R-HSA-451307 | Activation of Na-permeable kainate receptors | 3.328338e-02 | 1.478 |
| R-HSA-5579030 | Defective CYP19A1 causes AEXS | 3.328338e-02 | 1.478 |
| R-HSA-8952158 | RUNX3 regulates BCL2L11 (BIM) transcription | 3.980714e-02 | 1.400 |
| R-HSA-2644607 | Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | 3.980714e-02 | 1.400 |
| R-HSA-2644605 | FBXW7 Mutants and NOTCH1 in Cancer | 3.980714e-02 | 1.400 |
| R-HSA-5083630 | Defective LFNG causes SCDO3 | 3.980714e-02 | 1.400 |
| R-HSA-390522 | Striated Muscle Contraction | 3.047655e-02 | 1.516 |
| R-HSA-2173796 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 3.624297e-02 | 1.441 |
| R-HSA-191650 | Regulation of gap junction activity | 3.980714e-02 | 1.400 |
| R-HSA-3214847 | HATs acetylate histones | 3.922158e-02 | 1.406 |
| R-HSA-6798695 | Neutrophil degranulation | 4.421567e-02 | 1.354 |
| R-HSA-72766 | Translation | 3.369145e-02 | 1.472 |
| R-HSA-157118 | Signaling by NOTCH | 3.232965e-02 | 1.490 |
| R-HSA-8878159 | Transcriptional regulation by RUNX3 | 3.747698e-02 | 1.426 |
| R-HSA-199991 | Membrane Trafficking | 3.814126e-02 | 1.419 |
| R-HSA-8939211 | ESR-mediated signaling | 3.098684e-02 | 1.509 |
| R-HSA-202433 | Generation of second messenger molecules | 4.082060e-02 | 1.389 |
| R-HSA-8964539 | Glutamate and glutamine metabolism | 3.047655e-02 | 1.516 |
| R-HSA-983695 | Antigen activates B Cell Receptor (BCR) leading to generation of second messenge... | 3.329530e-02 | 1.478 |
| R-HSA-8941326 | RUNX2 regulates bone development | 3.476447e-02 | 1.459 |
| R-HSA-9615017 | FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 4.398701e-02 | 1.357 |
| R-HSA-8957322 | Metabolism of steroids | 2.994149e-02 | 1.524 |
| R-HSA-9678108 | SARS-CoV-1 Infection | 4.338300e-02 | 1.363 |
| R-HSA-9820965 | Respiratory syncytial virus (RSV) genome replication, transcription and translat... | 3.927141e-02 | 1.406 |
| R-HSA-9032759 | NTRK2 activates RAC1 | 4.628727e-02 | 1.335 |
| R-HSA-9673768 | Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | 4.628727e-02 | 1.335 |
| R-HSA-8866376 | Reelin signalling pathway | 4.628727e-02 | 1.335 |
| R-HSA-2173789 | TGF-beta receptor signaling activates SMADs | 4.724168e-02 | 1.326 |
| R-HSA-2172127 | DAP12 interactions | 4.890121e-02 | 1.311 |
| R-HSA-373752 | Netrin-1 signaling | 4.890121e-02 | 1.311 |
| R-HSA-190828 | Gap junction trafficking | 4.890121e-02 | 1.311 |
| R-HSA-69231 | Cyclin D associated events in G1 | 4.890121e-02 | 1.311 |
| R-HSA-69236 | G1 Phase | 4.890121e-02 | 1.311 |
| R-HSA-774815 | Nucleosome assembly | 5.058173e-02 | 1.296 |
| R-HSA-606279 | Deposition of new CENPA-containing nucleosomes at the centromere | 5.058173e-02 | 1.296 |
| R-HSA-76009 | Platelet Aggregation (Plug Formation) | 5.058173e-02 | 1.296 |
| R-HSA-9824272 | Somitogenesis | 5.058173e-02 | 1.296 |
| R-HSA-2660826 | Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | 5.272407e-02 | 1.278 |
| R-HSA-2660825 | Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | 5.272407e-02 | 1.278 |
| R-HSA-182218 | Nef Mediated CD8 Down-regulation | 5.272407e-02 | 1.278 |
| R-HSA-8852405 | Signaling by MST1 | 5.272407e-02 | 1.278 |
| R-HSA-8937144 | Aryl hydrocarbon receptor signalling | 5.272407e-02 | 1.278 |
| R-HSA-8941855 | RUNX3 regulates CDKN1A transcription | 5.272407e-02 | 1.278 |
| R-HSA-1483191 | Synthesis of PC | 5.400430e-02 | 1.268 |
| R-HSA-9725371 | Nuclear events stimulated by ALK signaling in cancer | 5.574566e-02 | 1.254 |
| R-HSA-1280218 | Adaptive Immune System | 5.750474e-02 | 1.240 |
| R-HSA-9766229 | Degradation of CDH1 | 5.750662e-02 | 1.240 |
| R-HSA-9027283 | Erythropoietin activates STAT5 | 5.911782e-02 | 1.228 |
| R-HSA-69478 | G2/M DNA replication checkpoint | 5.911782e-02 | 1.228 |
| R-HSA-9818749 | Regulation of NFE2L2 gene expression | 5.911782e-02 | 1.228 |
| R-HSA-8866654 | E3 ubiquitin ligases ubiquitinate target proteins | 6.290370e-02 | 1.201 |
| R-HSA-5339562 | Uptake and actions of bacterial toxins | 6.290370e-02 | 1.201 |
| R-HSA-1257604 | PIP3 activates AKT signaling | 6.348210e-02 | 1.197 |
| R-HSA-1912399 | Pre-NOTCH Processing in the Endoplasmic Reticulum | 6.546881e-02 | 1.184 |
| R-HSA-9603381 | Activated NTRK3 signals through PI3K | 6.546881e-02 | 1.184 |
| R-HSA-418886 | Netrin mediated repulsion signals | 6.546881e-02 | 1.184 |
| R-HSA-3371599 | Defective HLCS causes multiple carboxylase deficiency | 6.546881e-02 | 1.184 |
| R-HSA-9027277 | Erythropoietin activates Phospholipase C gamma (PLCG) | 8.426803e-02 | 1.074 |
| R-HSA-390450 | Folding of actin by CCT/TriC | 8.426803e-02 | 1.074 |
| R-HSA-9027276 | Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 1.026925e-01 | 0.988 |
| R-HSA-2691232 | Constitutive Signaling by NOTCH1 HD Domain Mutants | 1.026925e-01 | 0.988 |
| R-HSA-2691230 | Signaling by NOTCH1 HD Domain Mutants in Cancer | 1.026925e-01 | 0.988 |
| R-HSA-9820865 | Z-decay: degradation of maternal mRNAs by zygotically expressed factors | 1.026925e-01 | 0.988 |
| R-HSA-3000484 | Scavenging by Class F Receptors | 1.026925e-01 | 0.988 |
| R-HSA-399956 | CRMPs in Sema3A signaling | 1.147709e-01 | 0.940 |
| R-HSA-177504 | Retrograde neurotrophin signalling | 1.147709e-01 | 0.940 |
| R-HSA-9027284 | Erythropoietin activates RAS | 1.207496e-01 | 0.918 |
| R-HSA-9673770 | Signaling by PDGFRA extracellular domain mutants | 1.207496e-01 | 0.918 |
| R-HSA-9673767 | Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 1.207496e-01 | 0.918 |
| R-HSA-354194 | GRB2:SOS provides linkage to MAPK signaling for Integrins | 1.266882e-01 | 0.897 |
| R-HSA-5637810 | Constitutive Signaling by EGFRvIII | 1.384465e-01 | 0.859 |
| R-HSA-5637812 | Signaling by EGFRvIII in Cancer | 1.384465e-01 | 0.859 |
| R-HSA-372708 | p130Cas linkage to MAPK signaling for integrins | 1.384465e-01 | 0.859 |
| R-HSA-9845323 | Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | 7.807627e-02 | 1.107 |
| R-HSA-2173793 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 7.035404e-02 | 1.153 |
| R-HSA-399955 | SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 1.266882e-01 | 0.897 |
| R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at... | 7.612130e-02 | 1.118 |
| R-HSA-8941856 | RUNX3 regulates NOTCH signaling | 1.026925e-01 | 0.988 |
| R-HSA-186797 | Signaling by PDGF | 8.203321e-02 | 1.086 |
| R-HSA-5693606 | DNA Double Strand Break Response | 9.218612e-02 | 1.035 |
| R-HSA-5250941 | Negative epigenetic regulation of rRNA expression | 1.201105e-01 | 0.920 |
| R-HSA-427413 | NoRC negatively regulates rRNA expression | 1.005578e-01 | 0.998 |
| R-HSA-5140745 | WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 8.426803e-02 | 1.074 |
| R-HSA-192905 | vRNP Assembly | 9.045078e-02 | 1.044 |
| R-HSA-9634285 | Constitutive Signaling by Overexpressed ERBB2 | 1.026925e-01 | 0.988 |
| R-HSA-8866427 | VLDLR internalisation and degradation | 1.026925e-01 | 0.988 |
| R-HSA-9933947 | Formation of the non-canonical BAF (ncBAF) complex | 1.087520e-01 | 0.964 |
| R-HSA-9603798 | Class I peroxisomal membrane protein import | 1.266882e-01 | 0.897 |
| R-HSA-9925563 | Developmental Lineage of Pancreatic Ductal Cells | 9.634555e-02 | 1.016 |
| R-HSA-390696 | Adrenoceptors | 7.177732e-02 | 1.144 |
| R-HSA-8876493 | InlA-mediated entry of Listeria monocytogenes into host cells | 9.045078e-02 | 1.044 |
| R-HSA-171007 | p38MAPK events | 1.207496e-01 | 0.918 |
| R-HSA-5099900 | WNT5A-dependent internalization of FZD4 | 1.266882e-01 | 0.897 |
| R-HSA-9793380 | Formation of paraxial mesoderm | 8.004700e-02 | 1.097 |
| R-HSA-193144 | Estrogen biosynthesis | 1.026925e-01 | 0.988 |
| R-HSA-5693532 | DNA Double-Strand Break Repair | 1.104748e-01 | 0.957 |
| R-HSA-428359 | Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RN... | 8.426803e-02 | 1.074 |
| R-HSA-69481 | G2/M Checkpoints | 7.248695e-02 | 1.140 |
| R-HSA-1679131 | Trafficking and processing of endosomal TLR | 1.026925e-01 | 0.988 |
| R-HSA-9735871 | SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 1.207496e-01 | 0.918 |
| R-HSA-1462054 | Alpha-defensins | 7.177732e-02 | 1.144 |
| R-HSA-210744 | Regulation of gene expression in late stage (branching morphogenesis) pancreatic... | 1.266882e-01 | 0.897 |
| R-HSA-5693607 | Processing of DNA double-strand break ends | 1.223384e-01 | 0.912 |
| R-HSA-430116 | GP1b-IX-V activation signalling | 7.804363e-02 | 1.108 |
| R-HSA-8878171 | Transcriptional regulation by RUNX1 | 8.654519e-02 | 1.063 |
| R-HSA-1253288 | Downregulation of ERBB4 signaling | 7.177732e-02 | 1.144 |
| R-HSA-428542 | Regulation of commissural axon pathfinding by SLIT and ROBO | 7.804363e-02 | 1.108 |
| R-HSA-6799990 | Metal sequestration by antimicrobial proteins | 8.426803e-02 | 1.074 |
| R-HSA-9933937 | Formation of the canonical BAF (cBAF) complex | 1.147709e-01 | 0.940 |
| R-HSA-9933946 | Formation of the embryonic stem cell BAF (esBAF) complex | 1.207496e-01 | 0.918 |
| R-HSA-3323169 | Defects in biotin (Btn) metabolism | 7.804363e-02 | 1.108 |
| R-HSA-9933939 | Formation of the polybromo-BAF (pBAF) complex | 1.147709e-01 | 0.940 |
| R-HSA-388844 | Receptor-type tyrosine-protein phosphatases | 1.266882e-01 | 0.897 |
| R-HSA-74160 | Gene expression (Transcription) | 7.629967e-02 | 1.117 |
| R-HSA-75105 | Fatty acyl-CoA biosynthesis | 9.844521e-02 | 1.007 |
| R-HSA-9659379 | Sensory processing of sound | 1.178931e-01 | 0.929 |
| R-HSA-8934903 | Receptor Mediated Mitophagy | 8.426803e-02 | 1.074 |
| R-HSA-9662360 | Sensory processing of sound by inner hair cells of the cochlea | 9.425909e-02 | 1.026 |
| R-HSA-8953854 | Metabolism of RNA | 1.264223e-01 | 0.898 |
| R-HSA-1445148 | Translocation of SLC2A4 (GLUT4) to the plasma membrane | 1.048208e-01 | 0.980 |
| R-HSA-397014 | Muscle contraction | 7.338868e-02 | 1.134 |
| R-HSA-9612973 | Autophagy | 1.147738e-01 | 0.940 |
| R-HSA-9662361 | Sensory processing of sound by outer hair cells of the cochlea | 7.035404e-02 | 1.153 |
| R-HSA-8852135 | Protein ubiquitination | 1.091323e-01 | 0.962 |
| R-HSA-1169408 | ISG15 antiviral mechanism | 1.091323e-01 | 0.962 |
| R-HSA-73857 | RNA Polymerase II Transcription | 1.161278e-01 | 0.935 |
| R-HSA-1640170 | Cell Cycle | 1.217201e-01 | 0.915 |
| R-HSA-391160 | Signal regulatory protein family interactions | 1.147709e-01 | 0.940 |
| R-HSA-8852276 | The role of GTSE1 in G2/M progression after G2 checkpoint | 8.203321e-02 | 1.086 |
| R-HSA-9013694 | Signaling by NOTCH4 | 1.069706e-01 | 0.971 |
| R-HSA-1295596 | Spry regulation of FGF signaling | 1.207496e-01 | 0.918 |
| R-HSA-5621480 | Dectin-2 family | 7.225988e-02 | 1.141 |
| R-HSA-983705 | Signaling by the B Cell Receptor (BCR) | 1.176749e-01 | 0.929 |
| R-HSA-2151201 | Transcriptional activation of mitochondrial biogenesis | 1.223384e-01 | 0.912 |
| R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | 7.338868e-02 | 1.134 |
| R-HSA-9020558 | Interleukin-2 signaling | 9.045078e-02 | 1.044 |
| R-HSA-75205 | Dissolution of Fibrin Clot | 9.045078e-02 | 1.044 |
| R-HSA-177929 | Signaling by EGFR | 7.035404e-02 | 1.153 |
| R-HSA-5688426 | Deubiquitination | 1.171327e-01 | 0.931 |
| R-HSA-9024446 | NR1H2 and NR1H3-mediated signaling | 1.134904e-01 | 0.945 |
| R-HSA-9955298 | SLC-mediated transport of organic anions | 1.156863e-01 | 0.937 |
| R-HSA-8950505 | Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulati... | 8.808172e-02 | 1.055 |
| R-HSA-381038 | XBP1(S) activates chaperone genes | 1.359108e-01 | 0.867 |
| R-HSA-453279 | Mitotic G1 phase and G1/S transition | 1.006975e-01 | 0.997 |
| R-HSA-9020591 | Interleukin-12 signaling | 1.113057e-01 | 0.953 |
| R-HSA-9006925 | Intracellular signaling by second messengers | 9.999355e-02 | 1.000 |
| R-HSA-9694516 | SARS-CoV-2 Infection | 1.061827e-01 | 0.974 |
| R-HSA-447115 | Interleukin-12 family signaling | 1.382050e-01 | 0.859 |
| R-HSA-5621481 | C-type lectin receptors (CLRs) | 1.387229e-01 | 0.858 |
| R-HSA-392499 | Metabolism of proteins | 1.399131e-01 | 0.854 |
| R-HSA-9663891 | Selective autophagy | 1.405078e-01 | 0.852 |
| R-HSA-5689880 | Ub-specific processing proteases | 1.418294e-01 | 0.848 |
| R-HSA-210993 | Tie2 Signaling | 1.442667e-01 | 0.841 |
| R-HSA-432142 | Platelet sensitization by LDL | 1.442667e-01 | 0.841 |
| R-HSA-416993 | Trafficking of GluR2-containing AMPA receptors | 1.442667e-01 | 0.841 |
| R-HSA-9665348 | Signaling by ERBB2 ECD mutants | 1.442667e-01 | 0.841 |
| R-HSA-180292 | GAB1 signalosome | 1.442667e-01 | 0.841 |
| R-HSA-156711 | Polo-like kinase mediated events | 1.442667e-01 | 0.841 |
| R-HSA-202424 | Downstream TCR signaling | 1.451381e-01 | 0.838 |
| R-HSA-8986944 | Transcriptional Regulation by MECP2 | 1.474653e-01 | 0.831 |
| R-HSA-381070 | IRE1alpha activates chaperones | 1.498003e-01 | 0.824 |
| R-HSA-1912420 | Pre-NOTCH Processing in Golgi | 1.500480e-01 | 0.824 |
| R-HSA-844456 | The NLRP3 inflammasome | 1.500480e-01 | 0.824 |
| R-HSA-9934037 | Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | 1.557905e-01 | 0.807 |
| R-HSA-445144 | Signal transduction by L1 | 1.557905e-01 | 0.807 |
| R-HSA-373753 | Nephrin family interactions | 1.557905e-01 | 0.807 |
| R-HSA-71288 | Creatine metabolism | 1.557905e-01 | 0.807 |
| R-HSA-9837999 | Mitochondrial protein degradation | 1.568493e-01 | 0.805 |
| R-HSA-168928 | DDX58/IFIH1-mediated induction of interferon-alpha/beta | 1.592131e-01 | 0.798 |
| R-HSA-1236382 | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 1.614946e-01 | 0.792 |
| R-HSA-5637815 | Signaling by Ligand-Responsive EGFR Variants in Cancer | 1.614946e-01 | 0.792 |
| R-HSA-167044 | Signalling to RAS | 1.614946e-01 | 0.792 |
| R-HSA-210991 | Basigin interactions | 1.614946e-01 | 0.792 |
| R-HSA-9954709 | Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | 1.615836e-01 | 0.792 |
| R-HSA-69275 | G2/M Transition | 1.625704e-01 | 0.789 |
| R-HSA-2730905 | Role of LAT2/NTAL/LAB on calcium mobilization | 1.639606e-01 | 0.785 |
| R-HSA-453274 | Mitotic G2-G2/M phases | 1.658403e-01 | 0.780 |
| R-HSA-170834 | Signaling by TGF-beta Receptor Complex | 1.663439e-01 | 0.779 |
| R-HSA-9034015 | Signaling by NTRK3 (TRKC) | 1.671605e-01 | 0.777 |
| R-HSA-8876384 | Listeria monocytogenes entry into host cells | 1.671605e-01 | 0.777 |
| R-HSA-9614085 | FOXO-mediated transcription | 1.711288e-01 | 0.767 |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 1.724385e-01 | 0.763 |
| R-HSA-350054 | Notch-HLH transcription pathway | 1.727885e-01 | 0.762 |
| R-HSA-8964038 | LDL clearance | 1.727885e-01 | 0.762 |
| R-HSA-9009391 | Extra-nuclear estrogen signaling | 1.759367e-01 | 0.755 |
| R-HSA-9842860 | Regulation of endogenous retroelements | 1.783488e-01 | 0.749 |
| R-HSA-389957 | Prefoldin mediated transfer of substrate to CCT/TriC | 1.783788e-01 | 0.749 |
| R-HSA-200425 | Carnitine shuttle | 1.783788e-01 | 0.749 |
| R-HSA-982772 | Growth hormone receptor signaling | 1.783788e-01 | 0.749 |
| R-HSA-8856825 | Cargo recognition for clathrin-mediated endocytosis | 1.831885e-01 | 0.737 |
| R-HSA-9860931 | Response of endothelial cells to shear stress | 1.831885e-01 | 0.737 |
| R-HSA-429947 | Deadenylation of mRNA | 1.839316e-01 | 0.735 |
| R-HSA-9665686 | Signaling by ERBB2 TMD/JMD mutants | 1.839316e-01 | 0.735 |
| R-HSA-9821993 | Replacement of protamines by nucleosomes in the male pronucleus | 1.839316e-01 | 0.735 |
| R-HSA-418592 | ADP signalling through P2Y purinoceptor 1 | 1.839316e-01 | 0.735 |
| R-HSA-389948 | Co-inhibition by PD-1 | 1.858546e-01 | 0.731 |
| R-HSA-9932444 | ATP-dependent chromatin remodelers | 1.894473e-01 | 0.723 |
| R-HSA-9932451 | SWI/SNF chromatin remodelers | 1.894473e-01 | 0.723 |
| R-HSA-3214842 | HDMs demethylate histones | 1.894473e-01 | 0.723 |
| R-HSA-9620244 | Long-term potentiation | 1.894473e-01 | 0.723 |
| R-HSA-9839394 | TGFBR3 expression | 1.894473e-01 | 0.723 |
| R-HSA-5218921 | VEGFR2 mediated cell proliferation | 1.894473e-01 | 0.723 |
| R-HSA-5601884 | PIWI-interacting RNA (piRNA) biogenesis | 1.894473e-01 | 0.723 |
| R-HSA-211000 | Gene Silencing by RNA | 1.929248e-01 | 0.715 |
| R-HSA-1643713 | Signaling by EGFR in Cancer | 1.949260e-01 | 0.710 |
| R-HSA-2122948 | Activated NOTCH1 Transmits Signal to the Nucleus | 1.949260e-01 | 0.710 |
| R-HSA-8874081 | MET activates PTK2 signaling | 1.949260e-01 | 0.710 |
| R-HSA-70635 | Urea cycle | 1.949260e-01 | 0.710 |
| R-HSA-8934593 | Regulation of RUNX1 Expression and Activity | 1.949260e-01 | 0.710 |
| R-HSA-202403 | TCR signaling | 2.002715e-01 | 0.698 |
| R-HSA-171306 | Packaging Of Telomere Ends | 2.003681e-01 | 0.698 |
| R-HSA-73728 | RNA Polymerase I Promoter Opening | 2.003681e-01 | 0.698 |
| R-HSA-6803157 | Antimicrobial peptides | 2.027280e-01 | 0.693 |
| R-HSA-112315 | Transmission across Chemical Synapses | 2.035760e-01 | 0.691 |
| R-HSA-622312 | Inflammasomes | 2.057736e-01 | 0.687 |
| R-HSA-5654732 | Negative regulation of FGFR3 signaling | 2.057736e-01 | 0.687 |
| R-HSA-69278 | Cell Cycle, Mitotic | 2.077156e-01 | 0.683 |
| R-HSA-9855142 | Cellular responses to mechanical stimuli | 2.101180e-01 | 0.678 |
| R-HSA-5693567 | HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 2.101180e-01 | 0.678 |
| R-HSA-9006335 | Signaling by Erythropoietin | 2.111430e-01 | 0.675 |
| R-HSA-5334118 | DNA methylation | 2.111430e-01 | 0.675 |
| R-HSA-9664565 | Signaling by ERBB2 KD Mutants | 2.111430e-01 | 0.675 |
| R-HSA-5654733 | Negative regulation of FGFR4 signaling | 2.111430e-01 | 0.675 |
| R-HSA-1474244 | Extracellular matrix organization | 2.148072e-01 | 0.668 |
| R-HSA-1227990 | Signaling by ERBB2 in Cancer | 2.164764e-01 | 0.665 |
| R-HSA-456926 | Thrombin signalling through proteinase activated receptors (PARs) | 2.164764e-01 | 0.665 |
| R-HSA-9008059 | Interleukin-37 signaling | 2.164764e-01 | 0.665 |
| R-HSA-8863795 | Downregulation of ERBB2 signaling | 2.164764e-01 | 0.665 |
| R-HSA-9013508 | NOTCH3 Intracellular Domain Regulates Transcription | 2.164764e-01 | 0.665 |
| R-HSA-1474151 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 2.164764e-01 | 0.665 |
| R-HSA-389958 | Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 2.217741e-01 | 0.654 |
| R-HSA-399719 | Trafficking of AMPA receptors | 2.217741e-01 | 0.654 |
| R-HSA-1592230 | Mitochondrial biogenesis | 2.224938e-01 | 0.653 |
| R-HSA-5693538 | Homology Directed Repair | 2.249765e-01 | 0.648 |
| R-HSA-110330 | Recognition and association of DNA glycosylase with site containing an affected ... | 2.270362e-01 | 0.644 |
| R-HSA-8878166 | Transcriptional regulation by RUNX2 | 2.274614e-01 | 0.643 |
| R-HSA-176187 | Activation of ATR in response to replication stress | 2.322632e-01 | 0.634 |
| R-HSA-68616 | Assembly of the ORC complex at the origin of replication | 2.322632e-01 | 0.634 |
| R-HSA-399721 | Glutamate binding, activation of AMPA receptors and synaptic plasticity | 2.322632e-01 | 0.634 |
| R-HSA-5675482 | Regulation of necroptotic cell death | 2.322632e-01 | 0.634 |
| R-HSA-69273 | Cyclin A/B1/B2 associated events during G2/M transition | 2.322632e-01 | 0.634 |
| R-HSA-5654726 | Negative regulation of FGFR1 signaling | 2.322632e-01 | 0.634 |
| R-HSA-73886 | Chromosome Maintenance | 2.324371e-01 | 0.634 |
| R-HSA-9759194 | Nuclear events mediated by NFE2L2 | 2.324371e-01 | 0.634 |
| R-HSA-112316 | Neuronal System | 2.372604e-01 | 0.625 |
| R-HSA-9816359 | Maternal to zygotic transition (MZT) | 2.374199e-01 | 0.624 |
| R-HSA-2132295 | MHC class II antigen presentation | 2.374199e-01 | 0.624 |
| R-HSA-5696394 | DNA Damage Recognition in GG-NER | 2.374551e-01 | 0.624 |
| R-HSA-199220 | Vitamin B5 (pantothenate) metabolism | 2.374551e-01 | 0.624 |
| R-HSA-196849 | Metabolism of water-soluble vitamins and cofactors | 2.400839e-01 | 0.620 |
| R-HSA-9843970 | Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | 2.426122e-01 | 0.615 |
| R-HSA-203615 | eNOS activation | 2.426122e-01 | 0.615 |
| R-HSA-983170 | Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 2.426122e-01 | 0.615 |
| R-HSA-5673000 | RAF activation | 2.426122e-01 | 0.615 |
| R-HSA-5654727 | Negative regulation of FGFR2 signaling | 2.426122e-01 | 0.615 |
| R-HSA-392518 | Signal amplification | 2.426122e-01 | 0.615 |
| R-HSA-110328 | Recognition and association of DNA glycosylase with site containing an affected ... | 2.426122e-01 | 0.615 |
| R-HSA-5205647 | Mitophagy | 2.426122e-01 | 0.615 |
| R-HSA-3247509 | Chromatin modifying enzymes | 2.472820e-01 | 0.607 |
| R-HSA-9860927 | Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZ... | 2.477347e-01 | 0.606 |
| R-HSA-5693616 | Presynaptic phase of homologous DNA pairing and strand exchange | 2.477347e-01 | 0.606 |
| R-HSA-187687 | Signalling to ERKs | 2.477347e-01 | 0.606 |
| R-HSA-3296482 | Defects in vitamin and cofactor metabolism | 2.477347e-01 | 0.606 |
| R-HSA-187037 | Signaling by NTRK1 (TRKA) | 2.523998e-01 | 0.598 |
| R-HSA-212300 | PRC2 methylates histones and DNA | 2.528229e-01 | 0.597 |
| R-HSA-8853659 | RET signaling | 2.528229e-01 | 0.597 |
| R-HSA-73894 | DNA Repair | 2.568363e-01 | 0.590 |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression | 2.578770e-01 | 0.589 |
| R-HSA-110331 | Cleavage of the damaged purine | 2.578770e-01 | 0.589 |
| R-HSA-196854 | Metabolism of vitamins and cofactors | 2.627684e-01 | 0.580 |
| R-HSA-202131 | Metabolism of nitric oxide: NOS3 activation and regulation | 2.628973e-01 | 0.580 |
| R-HSA-8875878 | MET promotes cell motility | 2.628973e-01 | 0.580 |
| R-HSA-73927 | Depurination | 2.628973e-01 | 0.580 |
| R-HSA-5693579 | Homologous DNA Pairing and Strand Exchange | 2.628973e-01 | 0.580 |
| R-HSA-452723 | Transcriptional regulation of pluripotent stem cells | 2.628973e-01 | 0.580 |
| R-HSA-5213460 | RIPK1-mediated regulated necrosis | 2.628973e-01 | 0.580 |
| R-HSA-212436 | Generic Transcription Pathway | 2.658310e-01 | 0.575 |
| R-HSA-8964043 | Plasma lipoprotein clearance | 2.678839e-01 | 0.572 |
| R-HSA-8953750 | Transcriptional Regulation by E2F6 | 2.678839e-01 | 0.572 |
| R-HSA-201556 | Signaling by ALK | 2.678839e-01 | 0.572 |
| R-HSA-9670095 | Inhibition of DNA recombination at telomere | 2.728370e-01 | 0.564 |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 2.728370e-01 | 0.564 |
| R-HSA-8941858 | Regulation of RUNX3 expression and activity | 2.728370e-01 | 0.564 |
| R-HSA-9646399 | Aggrephagy | 2.728370e-01 | 0.564 |
| R-HSA-1251985 | Nuclear signaling by ERBB4 | 2.728370e-01 | 0.564 |
| R-HSA-451927 | Interleukin-2 family signaling | 2.728370e-01 | 0.564 |
| R-HSA-4839726 | Chromatin organization | 2.745523e-01 | 0.561 |
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated gene... | 2.777570e-01 | 0.556 |
| R-HSA-9821002 | Chromatin modifications during the maternal to zygotic transition (MZT) | 2.777570e-01 | 0.556 |
| R-HSA-5218920 | VEGFR2 mediated vascular permeability | 2.777570e-01 | 0.556 |
| R-HSA-9820841 | M-decay: degradation of maternal mRNAs by maternally stored factors | 2.777570e-01 | 0.556 |
| R-HSA-3214841 | PKMTs methylate histone lysines | 2.777570e-01 | 0.556 |
| R-HSA-73817 | Purine ribonucleoside monophosphate biosynthesis | 2.777570e-01 | 0.556 |
| R-HSA-9820952 | Respiratory Syncytial Virus Infection Pathway | 2.799123e-01 | 0.553 |
| R-HSA-3000480 | Scavenging by Class A Receptors | 2.826440e-01 | 0.549 |
| R-HSA-379716 | Cytosolic tRNA aminoacylation | 2.874982e-01 | 0.541 |
| R-HSA-110329 | Cleavage of the damaged pyrimidine | 2.874982e-01 | 0.541 |
| R-HSA-73928 | Depyrimidination | 2.874982e-01 | 0.541 |
| R-HSA-1632852 | Macroautophagy | 2.899085e-01 | 0.538 |
| R-HSA-69620 | Cell Cycle Checkpoints | 2.910721e-01 | 0.536 |
| R-HSA-9710421 | Defective pyroptosis | 2.923198e-01 | 0.534 |
| R-HSA-1461973 | Defensins | 2.923198e-01 | 0.534 |
| R-HSA-5654743 | Signaling by FGFR4 | 2.923198e-01 | 0.534 |
| R-HSA-9705671 | SARS-CoV-2 activates/modulates innate and adaptive immune responses | 2.949013e-01 | 0.530 |
| R-HSA-3214858 | RMTs methylate histone arginines | 2.971091e-01 | 0.527 |
| R-HSA-375280 | Amine ligand-binding receptors | 2.971091e-01 | 0.527 |
| R-HSA-156581 | Methylation | 2.971091e-01 | 0.527 |
| R-HSA-69613 | p53-Independent G1/S DNA Damage Checkpoint | 3.018663e-01 | 0.520 |
| R-HSA-69601 | Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | 3.018663e-01 | 0.520 |
| R-HSA-9824585 | Regulation of MITF-M-dependent genes involved in pigmentation | 3.018663e-01 | 0.520 |
| R-HSA-5654741 | Signaling by FGFR3 | 3.018663e-01 | 0.520 |
| R-HSA-2299718 | Condensation of Prophase Chromosomes | 3.065916e-01 | 0.513 |
| R-HSA-9664424 | Cell recruitment (pro-inflammatory response) | 3.065916e-01 | 0.513 |
| R-HSA-9660826 | Purinergic signaling in leishmaniasis infection | 3.065916e-01 | 0.513 |
| R-HSA-9839373 | Signaling by TGFBR3 | 3.065916e-01 | 0.513 |
| R-HSA-199977 | ER to Golgi Anterograde Transport | 3.073615e-01 | 0.512 |
| R-HSA-6811440 | Retrograde transport at the Trans-Golgi-Network | 3.112853e-01 | 0.507 |
| R-HSA-2173782 | Binding and Uptake of Ligands by Scavenger Receptors | 3.148188e-01 | 0.502 |
| R-HSA-5693571 | Nonhomologous End-Joining (NHEJ) | 3.159474e-01 | 0.500 |
| R-HSA-9634597 | GPER1 signaling | 3.159474e-01 | 0.500 |
| R-HSA-9755511 | KEAP1-NFE2L2 pathway | 3.173009e-01 | 0.499 |
| R-HSA-9820448 | Developmental Cell Lineages of the Exocrine Pancreas | 3.197811e-01 | 0.495 |
| R-HSA-2122947 | NOTCH1 Intracellular Domain Regulates Transcription | 3.205782e-01 | 0.494 |
| R-HSA-1169410 | Antiviral mechanism by IFN-stimulated genes | 3.247351e-01 | 0.488 |
| R-HSA-912446 | Meiotic recombination | 3.297470e-01 | 0.482 |
| R-HSA-72187 | mRNA 3'-end processing | 3.342853e-01 | 0.476 |
| R-HSA-112382 | Formation of RNA Pol II elongation complex | 3.342853e-01 | 0.476 |
| R-HSA-73772 | RNA Polymerase I Promoter Escape | 3.342853e-01 | 0.476 |
| R-HSA-1221632 | Meiotic synapsis | 3.387931e-01 | 0.470 |
| R-HSA-432722 | Golgi Associated Vesicle Biogenesis | 3.387931e-01 | 0.470 |
| R-HSA-75955 | RNA Polymerase II Transcription Elongation | 3.387931e-01 | 0.470 |
| R-HSA-445355 | Smooth Muscle Contraction | 3.387931e-01 | 0.470 |
| R-HSA-8956320 | Nucleotide biosynthesis | 3.387931e-01 | 0.470 |
| R-HSA-9006936 | Signaling by TGFB family members | 3.395409e-01 | 0.469 |
| R-HSA-73929 | Base-Excision Repair, AP Site Formation | 3.432707e-01 | 0.464 |
| R-HSA-3214815 | HDACs deacetylate histones | 3.477182e-01 | 0.459 |
| R-HSA-9012852 | Signaling by NOTCH3 | 3.477182e-01 | 0.459 |
| R-HSA-5578775 | Ion homeostasis | 3.521359e-01 | 0.453 |
| R-HSA-5654736 | Signaling by FGFR1 | 3.521359e-01 | 0.453 |
| R-HSA-1483257 | Phospholipid metabolism | 3.594044e-01 | 0.444 |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex | 3.608826e-01 | 0.443 |
| R-HSA-9033241 | Peroxisomal protein import | 3.652119e-01 | 0.437 |
| R-HSA-429914 | Deadenylation-dependent mRNA decay | 3.652119e-01 | 0.437 |
| R-HSA-191859 | snRNP Assembly | 3.652119e-01 | 0.437 |
| R-HSA-194441 | Metabolism of non-coding RNA | 3.652119e-01 | 0.437 |
| R-HSA-186712 | Regulation of beta-cell development | 3.652119e-01 | 0.437 |
| R-HSA-418555 | G alpha (s) signalling events | 3.688447e-01 | 0.433 |
| R-HSA-2644603 | Signaling by NOTCH1 in Cancer | 3.695122e-01 | 0.432 |
| R-HSA-2894858 | Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 3.695122e-01 | 0.432 |
| R-HSA-2644602 | Signaling by NOTCH1 PEST Domain Mutants in Cancer | 3.695122e-01 | 0.432 |
| R-HSA-2894862 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 3.695122e-01 | 0.432 |
| R-HSA-2644606 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | 3.695122e-01 | 0.432 |
| R-HSA-379724 | tRNA Aminoacylation | 3.695122e-01 | 0.432 |
| R-HSA-9764725 | Negative Regulation of CDH1 Gene Transcription | 3.695122e-01 | 0.432 |
| R-HSA-73856 | RNA Polymerase II Transcription Termination | 3.737836e-01 | 0.427 |
| R-HSA-211976 | Endogenous sterols | 3.737836e-01 | 0.427 |
| R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence | 3.780264e-01 | 0.422 |
| R-HSA-9616222 | Transcriptional regulation of granulopoiesis | 3.780264e-01 | 0.422 |
| R-HSA-1660499 | Synthesis of PIPs at the plasma membrane | 3.780264e-01 | 0.422 |
| R-HSA-983231 | Factors involved in megakaryocyte development and platelet production | 3.785050e-01 | 0.422 |
| R-HSA-380284 | Loss of proteins required for interphase microtubule organization from the centr... | 3.822407e-01 | 0.418 |
| R-HSA-380259 | Loss of Nlp from mitotic centrosomes | 3.822407e-01 | 0.418 |
| R-HSA-6799198 | Complex I biogenesis | 3.822407e-01 | 0.418 |
| R-HSA-69615 | G1/S DNA Damage Checkpoints | 3.822407e-01 | 0.418 |
| R-HSA-5690714 | CD22 mediated BCR regulation | 3.864266e-01 | 0.413 |
| R-HSA-936837 | Ion transport by P-type ATPases | 3.864266e-01 | 0.413 |
| R-HSA-168643 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signali... | 3.864266e-01 | 0.413 |
| R-HSA-8854518 | AURKA Activation by TPX2 | 3.947144e-01 | 0.404 |
| R-HSA-9909649 | Regulation of PD-L1(CD274) transcription | 3.947144e-01 | 0.404 |
| R-HSA-5685942 | HDR through Homologous Recombination (HRR) | 3.988166e-01 | 0.399 |
| R-HSA-196071 | Metabolism of steroid hormones | 3.988166e-01 | 0.399 |
| R-HSA-8936459 | RUNX1 regulates genes involved in megakaryocyte differentiation and platelet fun... | 4.028913e-01 | 0.395 |
| R-HSA-5218859 | Regulated Necrosis | 4.028913e-01 | 0.395 |
| R-HSA-1852241 | Organelle biogenesis and maintenance | 4.051898e-01 | 0.392 |
| R-HSA-212165 | Epigenetic regulation of gene expression | 4.106298e-01 | 0.387 |
| R-HSA-9843940 | Regulation of endogenous retroelements by KRAB-ZFP proteins | 4.109587e-01 | 0.386 |
| R-HSA-204005 | COPII-mediated vesicle transport | 4.109587e-01 | 0.386 |
| R-HSA-9764560 | Regulation of CDH1 Gene Transcription | 4.109587e-01 | 0.386 |
| R-HSA-69202 | Cyclin E associated events during G1/S transition | 4.109587e-01 | 0.386 |
| R-HSA-3906995 | Diseases associated with O-glycosylation of proteins | 4.149518e-01 | 0.382 |
| R-HSA-8978934 | Metabolism of cofactors | 4.149518e-01 | 0.382 |
| R-HSA-9856649 | Transcriptional and post-translational regulation of MITF-M expression and activ... | 4.149518e-01 | 0.382 |
| R-HSA-199992 | trans-Golgi Network Vesicle Budding | 4.189181e-01 | 0.378 |
| R-HSA-5578749 | Transcriptional regulation by small RNAs | 4.189181e-01 | 0.378 |
| R-HSA-69656 | Cyclin A:Cdk2-associated events at S phase entry | 4.189181e-01 | 0.378 |
| R-HSA-159236 | Transport of Mature mRNA derived from an Intron-Containing Transcript | 4.228578e-01 | 0.374 |
| R-HSA-380270 | Recruitment of mitotic centrosome proteins and complexes | 4.228578e-01 | 0.374 |
| R-HSA-72163 | mRNA Splicing - Major Pathway | 4.235058e-01 | 0.373 |
| R-HSA-674695 | RNA Polymerase II Pre-transcription Events | 4.267709e-01 | 0.370 |
| R-HSA-1236394 | Signaling by ERBB4 | 4.267709e-01 | 0.370 |
| R-HSA-380287 | Centrosome maturation | 4.306578e-01 | 0.366 |
| R-HSA-1980143 | Signaling by NOTCH1 | 4.345186e-01 | 0.362 |
| R-HSA-73854 | RNA Polymerase I Promoter Clearance | 4.345186e-01 | 0.362 |
| R-HSA-5689603 | UCH proteinases | 4.345186e-01 | 0.362 |
| R-HSA-948021 | Transport to the Golgi and subsequent modification | 4.419601e-01 | 0.355 |
| R-HSA-73864 | RNA Polymerase I Transcription | 4.421625e-01 | 0.354 |
| R-HSA-4086400 | PCP/CE pathway | 4.421625e-01 | 0.354 |
| R-HSA-2454202 | Fc epsilon receptor (FCERI) signaling | 4.442445e-01 | 0.352 |
| R-HSA-1483206 | Glycerophospholipid biosynthesis | 4.442445e-01 | 0.352 |
| R-HSA-5579029 | Metabolic disorders of biological oxidation enzymes | 4.459460e-01 | 0.351 |
| R-HSA-72172 | mRNA Splicing | 4.487980e-01 | 0.348 |
| R-HSA-6806834 | Signaling by MET | 4.497040e-01 | 0.347 |
| R-HSA-9856530 | High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR... | 4.497040e-01 | 0.347 |
| R-HSA-5654738 | Signaling by FGFR2 | 4.497040e-01 | 0.347 |
| R-HSA-977225 | Amyloid fiber formation | 4.534368e-01 | 0.343 |
| R-HSA-72202 | Transport of Mature Transcript to Cytoplasm | 4.571445e-01 | 0.340 |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) | 4.571445e-01 | 0.340 |
| R-HSA-2565942 | Regulation of PLK1 Activity at G2/M Transition | 4.644852e-01 | 0.333 |
| R-HSA-8939236 | RUNX1 regulates transcription of genes involved in differentiation of HSCs | 4.644852e-01 | 0.333 |
| R-HSA-5696399 | Global Genome Nucleotide Excision Repair (GG-NER) | 4.644852e-01 | 0.333 |
| R-HSA-597592 | Post-translational protein modification | 4.674069e-01 | 0.330 |
| R-HSA-1500620 | Meiosis | 4.681187e-01 | 0.330 |
| R-HSA-6794362 | Protein-protein interactions at synapses | 4.681187e-01 | 0.330 |
| R-HSA-9730414 | MITF-M-regulated melanocyte development | 4.690293e-01 | 0.329 |
| R-HSA-6807505 | RNA polymerase II transcribes snRNA genes | 4.753124e-01 | 0.323 |
| R-HSA-6804756 | Regulation of TP53 Activity through Phosphorylation | 4.753124e-01 | 0.323 |
| R-HSA-390466 | Chaperonin-mediated protein folding | 4.788730e-01 | 0.320 |
| R-HSA-438064 | Post NMDA receptor activation events | 4.788730e-01 | 0.320 |
| R-HSA-380320 | Recruitment of NuMA to mitotic centrosomes | 4.824097e-01 | 0.317 |
| R-HSA-9645723 | Diseases of programmed cell death | 4.824097e-01 | 0.317 |
| R-HSA-5620912 | Anchoring of the basal body to the plasma membrane | 4.894119e-01 | 0.310 |
| R-HSA-73884 | Base Excision Repair | 4.894119e-01 | 0.310 |
| R-HSA-391251 | Protein folding | 4.997395e-01 | 0.301 |
| R-HSA-174824 | Plasma lipoprotein assembly, remodeling, and clearance | 4.997395e-01 | 0.301 |
| R-HSA-68867 | Assembly of the pre-replicative complex | 5.031358e-01 | 0.298 |
| R-HSA-6807878 | COPI-mediated anterograde transport | 5.164942e-01 | 0.287 |
| R-HSA-5607764 | CLEC7A (Dectin-1) signaling | 5.164942e-01 | 0.287 |
| R-HSA-983169 | Class I MHC mediated antigen processing & presentation | 5.170902e-01 | 0.286 |
| R-HSA-157579 | Telomere Maintenance | 5.197778e-01 | 0.284 |
| R-HSA-8957275 | Post-translational protein phosphorylation | 5.230393e-01 | 0.281 |
| R-HSA-190236 | Signaling by FGFR | 5.230393e-01 | 0.281 |
| R-HSA-9824439 | Bacterial Infection Pathways | 5.286747e-01 | 0.277 |
| R-HSA-3371453 | Regulation of HSF1-mediated heat shock response | 5.358674e-01 | 0.271 |
| R-HSA-2559580 | Oxidative Stress Induced Senescence | 5.358674e-01 | 0.271 |
| R-HSA-442755 | Activation of NMDA receptors and postsynaptic events | 5.358674e-01 | 0.271 |
| R-HSA-1483255 | PI Metabolism | 5.358674e-01 | 0.271 |
| R-HSA-5619507 | Activation of HOX genes during differentiation | 5.452635e-01 | 0.263 |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogen... | 5.452635e-01 | 0.263 |
| R-HSA-5696398 | Nucleotide Excision Repair | 5.483534e-01 | 0.261 |
| R-HSA-418346 | Platelet homeostasis | 5.514226e-01 | 0.259 |
| R-HSA-69002 | DNA Replication Pre-Initiation | 5.605066e-01 | 0.251 |
| R-HSA-2871796 | FCERI mediated MAPK activation | 5.694083e-01 | 0.245 |
| R-HSA-9734767 | Developmental Cell Lineages | 5.729594e-01 | 0.242 |
| R-HSA-381426 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-l... | 5.781314e-01 | 0.238 |
| R-HSA-1430728 | Metabolism | 5.800137e-01 | 0.237 |
| R-HSA-9711123 | Cellular response to chemical stress | 5.825166e-01 | 0.235 |
| R-HSA-2029485 | Role of phospholipids in phagocytosis | 5.838492e-01 | 0.234 |
| R-HSA-2871809 | FCERI mediated Ca+2 mobilization | 5.838492e-01 | 0.234 |
| R-HSA-5668914 | Diseases of metabolism | 5.872773e-01 | 0.231 |
| R-HSA-68875 | Mitotic Prophase | 5.978101e-01 | 0.223 |
| R-HSA-211945 | Phase I - Functionalization of compounds | 6.011627e-01 | 0.221 |
| R-HSA-72203 | Processing of Capped Intron-Containing Pre-mRNA | 6.029928e-01 | 0.220 |
| R-HSA-983168 | Antigen processing: Ubiquitination & Proteasome degradation | 6.084459e-01 | 0.216 |
| R-HSA-9841922 | MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesi... | 6.139518e-01 | 0.212 |
| R-HSA-9851695 | Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | 6.139518e-01 | 0.212 |
| R-HSA-9818564 | Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | 6.139518e-01 | 0.212 |
| R-HSA-69206 | G1/S Transition | 6.139518e-01 | 0.212 |
| R-HSA-114608 | Platelet degranulation | 6.191884e-01 | 0.208 |
| R-HSA-1474165 | Reproduction | 6.294513e-01 | 0.201 |
| R-HSA-5576891 | Cardiac conduction | 6.319739e-01 | 0.199 |
| R-HSA-195721 | Signaling by WNT | 6.365788e-01 | 0.196 |
| R-HSA-76005 | Response to elevated platelet cytosolic Ca2+ | 6.369682e-01 | 0.196 |
| R-HSA-3700989 | Transcriptional Regulation by TP53 | 6.424866e-01 | 0.192 |
| R-HSA-3858494 | Beta-catenin independent WNT signaling | 6.467562e-01 | 0.189 |
| R-HSA-2871837 | FCERI mediated NF-kB activation | 6.678335e-01 | 0.175 |
| R-HSA-69242 | S Phase | 6.767965e-01 | 0.170 |
| R-HSA-9856651 | MITF-M-dependent gene expression | 6.811878e-01 | 0.167 |
| R-HSA-446652 | Interleukin-1 family signaling | 6.855199e-01 | 0.164 |
| R-HSA-9609507 | Protein localization | 6.876640e-01 | 0.163 |
| R-HSA-69306 | DNA Replication | 6.876640e-01 | 0.163 |
| R-HSA-9917777 | Epigenetic regulation by WDR5-containing histone modifying complexes | 6.897937e-01 | 0.161 |
| R-HSA-9610379 | HCMV Late Events | 6.960966e-01 | 0.157 |
| R-HSA-5633007 | Regulation of TP53 Activity | 7.022727e-01 | 0.153 |
| R-HSA-556833 | Metabolism of lipids | 7.025769e-01 | 0.153 |
| R-HSA-211897 | Cytochrome P450 - arranged by substrate type | 7.162041e-01 | 0.145 |
| R-HSA-211859 | Biological oxidations | 7.164844e-01 | 0.145 |
| R-HSA-9909648 | Regulation of PD-L1(CD274) expression | 7.276298e-01 | 0.138 |
| R-HSA-611105 | Respiratory electron transport | 7.385996e-01 | 0.132 |
| R-HSA-2559583 | Cellular Senescence | 7.421580e-01 | 0.130 |
| R-HSA-201681 | TCF dependent signaling in response to WNT | 7.474059e-01 | 0.126 |
| R-HSA-3781865 | Diseases of glycosylation | 7.491315e-01 | 0.125 |
| R-HSA-983712 | Ion channel transport | 7.575861e-01 | 0.121 |
| R-HSA-5617833 | Cilium Assembly | 7.592428e-01 | 0.120 |
| R-HSA-68886 | M Phase | 7.602465e-01 | 0.119 |
| R-HSA-168898 | Toll-like Receptor Cascades | 7.608883e-01 | 0.119 |
| R-HSA-913531 | Interferon Signaling | 7.614589e-01 | 0.118 |
| R-HSA-68877 | Mitotic Prometaphase | 7.641459e-01 | 0.117 |
| R-HSA-9609690 | HCMV Early Events | 7.689501e-01 | 0.114 |
| R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic | 7.752052e-01 | 0.111 |
| R-HSA-425407 | SLC-mediated transmembrane transport | 7.778876e-01 | 0.109 |
| R-HSA-5357801 | Programmed Cell Death | 7.842745e-01 | 0.106 |
| R-HSA-8978868 | Fatty acid metabolism | 7.890152e-01 | 0.103 |
| R-HSA-446203 | Asparagine N-linked glycosylation | 8.047956e-01 | 0.094 |
| R-HSA-8951664 | Neddylation | 8.067250e-01 | 0.093 |
| R-HSA-198933 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 8.170659e-01 | 0.088 |
| R-HSA-15869 | Metabolism of nucleotides | 8.256633e-01 | 0.083 |
| R-HSA-156580 | Phase II - Conjugation of compounds | 8.292242e-01 | 0.081 |
| R-HSA-9609646 | HCMV Infection | 8.416749e-01 | 0.075 |
| R-HSA-382551 | Transport of small molecules | 9.131683e-01 | 0.039 |
| R-HSA-1428517 | Aerobic respiration and respiratory electron transport | 9.155325e-01 | 0.038 |
| R-HSA-373076 | Class A/1 (Rhodopsin-like receptors) | 9.419201e-01 | 0.026 |
| R-HSA-418594 | G alpha (i) signalling events | 9.469381e-01 | 0.024 |
| R-HSA-388396 | GPCR downstream signalling | 9.732825e-01 | 0.012 |
| R-HSA-372790 | Signaling by GPCR | 9.838421e-01 | 0.007 |
| R-HSA-500792 | GPCR ligand binding | 9.851430e-01 | 0.007 |
| R-HSA-9709957 | Sensory Perception | 9.985560e-01 | 0.001 |
Download
| kinase | JSD_mean | pearson_surrounding | kinase_max_IC_position | max_position_JSD |
|---|---|---|---|---|
ABL2 |
0.811 | 0.187 | -1 | 0.823 |
BLK |
0.810 | 0.246 | -1 | 0.775 |
ABL1 |
0.810 | 0.177 | -1 | 0.839 |
LCK |
0.808 | 0.204 | -1 | 0.788 |
CSF1R |
0.808 | 0.180 | 3 | 0.732 |
MST1R |
0.806 | 0.143 | 3 | 0.720 |
TEC |
0.806 | 0.188 | -1 | 0.837 |
HCK |
0.806 | 0.166 | -1 | 0.798 |
PDHK3_TYR |
0.805 | -0.067 | 4 | 0.712 |
PKMYT1_TYR |
0.805 | 0.022 | 3 | 0.700 |
TYK2 |
0.805 | 0.101 | 1 | 0.752 |
RET |
0.804 | 0.083 | 1 | 0.733 |
YES1 |
0.804 | 0.130 | -1 | 0.828 |
JAK2 |
0.803 | 0.083 | 1 | 0.742 |
FER |
0.803 | 0.080 | 1 | 0.741 |
SRMS |
0.802 | 0.120 | 1 | 0.706 |
MAP2K4_TYR |
0.802 | -0.090 | -1 | 0.796 |
TXK |
0.802 | 0.111 | 1 | 0.657 |
TYRO3 |
0.802 | 0.081 | 3 | 0.694 |
EPHB4 |
0.802 | 0.084 | -1 | 0.777 |
KIT |
0.802 | 0.121 | 3 | 0.710 |
PINK1_TYR |
0.801 | 0.005 | 1 | 0.724 |
MAP2K7_TYR |
0.801 | -0.109 | 2 | 0.796 |
TESK1_TYR |
0.800 | -0.048 | 3 | 0.710 |
ROS1 |
0.800 | 0.085 | 3 | 0.696 |
ITK |
0.800 | 0.094 | -1 | 0.809 |
AXL |
0.800 | 0.147 | 3 | 0.724 |
BTK |
0.799 | 0.105 | -1 | 0.818 |
TNK2 |
0.799 | 0.117 | 3 | 0.705 |
LIMK2_TYR |
0.799 | -0.006 | -3 | 0.805 |
FLT3 |
0.798 | 0.107 | 3 | 0.695 |
EPHA6 |
0.798 | 0.068 | -1 | 0.754 |
BMX |
0.798 | 0.098 | -1 | 0.779 |
PDHK4_TYR |
0.798 | -0.069 | 2 | 0.823 |
FGR |
0.798 | 0.046 | 1 | 0.728 |
FGFR2 |
0.798 | 0.112 | 3 | 0.700 |
LYN |
0.798 | 0.128 | 3 | 0.631 |
MERTK |
0.798 | 0.135 | 3 | 0.718 |
JAK1 |
0.797 | 0.148 | 1 | 0.671 |
MAP2K6_TYR |
0.797 | -0.109 | -1 | 0.764 |
BMPR2_TYR |
0.797 | -0.049 | -1 | 0.739 |
LIMK1_TYR |
0.797 | -0.036 | 2 | 0.778 |
PDGFRB |
0.797 | 0.104 | 3 | 0.707 |
EPHA1 |
0.797 | 0.177 | 3 | 0.713 |
PTK6 |
0.796 | 0.056 | -1 | 0.834 |
KDR |
0.796 | 0.134 | 3 | 0.720 |
MET |
0.796 | 0.088 | 3 | 0.714 |
TNNI3K_TYR |
0.796 | 0.105 | 1 | 0.792 |
EPHB3 |
0.795 | 0.056 | -1 | 0.771 |
FRK |
0.795 | 0.103 | -1 | 0.799 |
DDR1 |
0.794 | -0.008 | 4 | 0.691 |
PDHK1_TYR |
0.794 | -0.116 | -1 | 0.774 |
JAK3 |
0.793 | 0.048 | 1 | 0.686 |
TEK |
0.793 | 0.037 | 3 | 0.656 |
MATK |
0.793 | 0.080 | -1 | 0.770 |
EPHB1 |
0.792 | 0.032 | 1 | 0.708 |
FYN |
0.792 | 0.083 | -1 | 0.761 |
WEE1_TYR |
0.792 | 0.087 | -1 | 0.795 |
PTK2B |
0.792 | 0.104 | -1 | 0.857 |
EPHA4 |
0.792 | 0.017 | 2 | 0.780 |
LTK |
0.792 | 0.059 | 3 | 0.648 |
FGFR1 |
0.792 | 0.039 | 3 | 0.685 |
INSRR |
0.791 | 0.022 | 3 | 0.675 |
EPHB2 |
0.791 | 0.029 | -1 | 0.769 |
PDGFRA |
0.791 | 0.059 | 3 | 0.704 |
EPHA7 |
0.791 | 0.084 | 2 | 0.776 |
ALK |
0.790 | 0.046 | 3 | 0.630 |
NTRK1 |
0.788 | 0.033 | -1 | 0.774 |
ERBB2 |
0.788 | 0.020 | 1 | 0.669 |
NTRK2 |
0.788 | 0.060 | 3 | 0.689 |
SRC |
0.787 | 0.071 | -1 | 0.803 |
FLT4 |
0.785 | 0.046 | 3 | 0.681 |
FGFR4 |
0.785 | 0.075 | -1 | 0.770 |
TNK1 |
0.785 | -0.006 | 3 | 0.683 |
EPHA5 |
0.785 | 0.063 | 2 | 0.768 |
NTRK3 |
0.784 | 0.054 | -1 | 0.749 |
EPHA3 |
0.784 | 0.006 | 2 | 0.745 |
FGFR3 |
0.784 | 0.037 | 3 | 0.689 |
FLT1 |
0.783 | 0.021 | -1 | 0.712 |
EPHA8 |
0.783 | 0.049 | -1 | 0.738 |
DDR2 |
0.783 | 0.050 | 3 | 0.668 |
NEK10_TYR |
0.782 | -0.047 | 1 | 0.611 |
CSK |
0.781 | 0.003 | 2 | 0.763 |
INSR |
0.781 | -0.001 | 3 | 0.659 |
EGFR |
0.780 | 0.031 | 1 | 0.584 |
EPHA2 |
0.774 | 0.032 | -1 | 0.702 |
MUSK |
0.772 | 0.008 | 1 | 0.578 |
ERBB4 |
0.767 | 0.009 | 1 | 0.581 |
IGF1R |
0.767 | -0.035 | 3 | 0.594 |
PTK2 |
0.766 | -0.016 | -1 | 0.614 |
SYK |
0.764 | -0.029 | -1 | 0.644 |
FES |
0.763 | 0.004 | -1 | 0.801 |
ZAP70 |
0.750 | -0.000 | -1 | 0.630 |
BMPR2 |
0.724 | 0.158 | -2 | 0.802 |
PKR |
0.721 | 0.124 | 1 | 0.776 |
PRPK |
0.720 | 0.066 | -1 | 0.812 |
TTK |
0.714 | 0.175 | -2 | 0.777 |
VRK2 |
0.714 | -0.058 | 1 | 0.775 |
GAK |
0.713 | 0.021 | 1 | 0.730 |
DSTYK |
0.712 | 0.096 | 2 | 0.841 |
ANKRD3 |
0.710 | 0.068 | 1 | 0.754 |
PERK |
0.710 | 0.072 | -2 | 0.796 |
HRI |
0.710 | 0.105 | -2 | 0.772 |
COT |
0.710 | 0.046 | 2 | 0.810 |
MOS |
0.709 | -0.033 | 1 | 0.739 |
ALK4 |
0.709 | 0.035 | -2 | 0.808 |
ALK2 |
0.709 | 0.071 | -2 | 0.802 |
TGFBR2 |
0.709 | 0.093 | -2 | 0.781 |
TNIK |
0.709 | 0.105 | 3 | 0.711 |
NIK |
0.708 | -0.042 | -3 | 0.790 |
MEKK2 |
0.708 | 0.061 | 2 | 0.727 |
TAK1 |
0.708 | 0.053 | 1 | 0.788 |
TLK2 |
0.708 | 0.051 | 1 | 0.806 |
MEKK1 |
0.708 | 0.095 | 1 | 0.759 |
VRK1 |
0.708 | 0.006 | 2 | 0.748 |
MLK1 |
0.707 | 0.076 | 2 | 0.739 |
PRP4 |
0.707 | 0.144 | -3 | 0.833 |
RAF1 |
0.707 | -0.021 | 1 | 0.734 |
PDHK4 |
0.707 | -0.051 | 1 | 0.738 |
CAMLCK |
0.707 | -0.025 | -2 | 0.707 |
ATR |
0.706 | -0.021 | 1 | 0.755 |
MINK |
0.706 | 0.065 | 1 | 0.717 |
TAO2 |
0.706 | 0.071 | 2 | 0.767 |
DAPK2 |
0.706 | -0.035 | -3 | 0.763 |
NLK |
0.705 | 0.005 | 1 | 0.691 |
RIPK3 |
0.705 | 0.125 | 3 | 0.710 |
HGK |
0.705 | 0.073 | 3 | 0.704 |
NEK5 |
0.705 | 0.024 | 1 | 0.757 |
CAMK2G |
0.705 | -0.017 | 2 | 0.833 |
ATM |
0.704 | 0.069 | 1 | 0.697 |
WNK1 |
0.704 | 0.042 | -2 | 0.745 |
CDKL1 |
0.704 | 0.000 | -3 | 0.700 |
MEK1 |
0.704 | -0.117 | 2 | 0.780 |
NEK1 |
0.704 | 0.026 | 1 | 0.726 |
TGFBR1 |
0.703 | 0.038 | -2 | 0.791 |
MEK5 |
0.703 | -0.045 | 2 | 0.748 |
PDHK1 |
0.703 | -0.059 | 1 | 0.769 |
NEK9 |
0.702 | 0.012 | 2 | 0.751 |
CAMK1B |
0.702 | -0.080 | -3 | 0.745 |
SKMLCK |
0.702 | 0.033 | -2 | 0.707 |
DLK |
0.702 | -0.110 | 1 | 0.716 |
NEK7 |
0.702 | 0.010 | -3 | 0.752 |
ALPHAK3 |
0.702 | 0.034 | -1 | 0.744 |
IRE1 |
0.701 | 0.095 | 1 | 0.740 |
NEK6 |
0.701 | 0.050 | -2 | 0.786 |
LRRK2 |
0.701 | -0.040 | 2 | 0.782 |
TAO3 |
0.701 | 0.020 | 1 | 0.695 |
TBK1 |
0.701 | -0.009 | 1 | 0.660 |
GCN2 |
0.701 | -0.020 | 2 | 0.747 |
BMPR1B |
0.701 | 0.048 | 1 | 0.595 |
WNK3 |
0.700 | 0.002 | 1 | 0.750 |
TLK1 |
0.700 | -0.000 | -2 | 0.769 |
BRAF |
0.700 | -0.038 | -4 | 0.782 |
WNK4 |
0.700 | 0.044 | -2 | 0.748 |
PINK1 |
0.700 | 0.068 | 1 | 0.794 |
MYO3B |
0.700 | 0.100 | 2 | 0.737 |
ACVR2A |
0.699 | 0.022 | -2 | 0.770 |
NEK4 |
0.699 | 0.012 | 1 | 0.726 |
IRE2 |
0.699 | 0.095 | 2 | 0.674 |
NEK8 |
0.699 | 0.002 | 2 | 0.740 |
ACVR2B |
0.699 | 0.025 | -2 | 0.776 |
IKKE |
0.699 | -0.018 | 1 | 0.666 |
MEKK6 |
0.699 | 0.045 | 1 | 0.730 |
ZAK |
0.698 | 0.035 | 1 | 0.703 |
LKB1 |
0.698 | -0.022 | -3 | 0.800 |
EEF2K |
0.698 | 0.002 | 3 | 0.645 |
LATS1 |
0.698 | 0.001 | -3 | 0.802 |
MST3 |
0.698 | 0.067 | 2 | 0.748 |
ERK5 |
0.698 | -0.012 | 1 | 0.669 |
GCK |
0.698 | -0.013 | 1 | 0.685 |
CLK3 |
0.698 | 0.021 | 1 | 0.728 |
MLK2 |
0.698 | -0.046 | 2 | 0.727 |
FAM20C |
0.697 | 0.203 | 2 | 0.792 |
YSK4 |
0.697 | -0.056 | 1 | 0.683 |
MEKK3 |
0.696 | -0.034 | 1 | 0.687 |
CAMKK1 |
0.696 | -0.075 | -2 | 0.682 |
IKKB |
0.696 | -0.056 | -2 | 0.665 |
CDC7 |
0.696 | -0.090 | 1 | 0.676 |
NEK2 |
0.696 | 0.023 | 2 | 0.736 |
MLK4 |
0.696 | 0.088 | 2 | 0.667 |
ASK1 |
0.696 | -0.023 | 1 | 0.670 |
MPSK1 |
0.695 | 0.024 | 1 | 0.770 |
RIPK1 |
0.695 | -0.063 | 1 | 0.697 |
ULK2 |
0.695 | -0.056 | 2 | 0.720 |
MST4 |
0.695 | 0.040 | 2 | 0.752 |
MYO3A |
0.695 | 0.071 | 1 | 0.713 |
MTOR |
0.695 | -0.078 | 1 | 0.643 |
OSR1 |
0.695 | 0.014 | 2 | 0.717 |
TTBK2 |
0.694 | -0.019 | 2 | 0.683 |
MST1 |
0.694 | -0.058 | 1 | 0.710 |
MLK3 |
0.694 | 0.060 | 2 | 0.683 |
PKN3 |
0.694 | -0.027 | -3 | 0.753 |
YSK1 |
0.694 | 0.059 | 2 | 0.722 |
GRK5 |
0.694 | -0.133 | -3 | 0.778 |
NUAK2 |
0.694 | -0.023 | -3 | 0.740 |
MARK4 |
0.694 | -0.030 | 4 | 0.673 |
SMG1 |
0.693 | 0.005 | 1 | 0.727 |
IRAK1 |
0.693 | 0.063 | -1 | 0.738 |
PIM3 |
0.693 | -0.056 | -3 | 0.764 |
CAMK2D |
0.693 | -0.009 | -3 | 0.742 |
KHS1 |
0.693 | 0.005 | 1 | 0.699 |
IRAK4 |
0.693 | 0.057 | 1 | 0.741 |
MASTL |
0.693 | -0.139 | -2 | 0.712 |
PLK1 |
0.693 | -0.041 | -2 | 0.764 |
CHAK2 |
0.693 | -0.072 | -1 | 0.711 |
DNAPK |
0.693 | 0.041 | 1 | 0.633 |
MST2 |
0.693 | -0.072 | 1 | 0.712 |
PKCD |
0.692 | 0.019 | 2 | 0.722 |
KHS2 |
0.692 | 0.022 | 1 | 0.695 |
CDKL5 |
0.692 | -0.003 | -3 | 0.687 |
MAP3K15 |
0.692 | -0.059 | 1 | 0.683 |
CHK1 |
0.691 | 0.012 | -3 | 0.780 |
GRK6 |
0.691 | -0.109 | 1 | 0.690 |
BMPR1A |
0.691 | 0.040 | 1 | 0.586 |
HPK1 |
0.691 | -0.005 | 1 | 0.657 |
AMPKA1 |
0.691 | -0.051 | -3 | 0.773 |
PDK1 |
0.691 | -0.088 | 1 | 0.670 |
SMMLCK |
0.690 | -0.017 | -3 | 0.717 |
BCKDK |
0.690 | -0.042 | -1 | 0.684 |
BIKE |
0.690 | 0.013 | 1 | 0.621 |
ICK |
0.690 | -0.067 | -3 | 0.725 |
GRK4 |
0.690 | -0.068 | -2 | 0.763 |
SRPK3 |
0.690 | 0.019 | -3 | 0.637 |
MAPKAPK3 |
0.689 | -0.006 | -3 | 0.707 |
CAMKK2 |
0.689 | -0.119 | -2 | 0.661 |
TAO1 |
0.689 | 0.073 | 1 | 0.655 |
PKN2 |
0.689 | 0.005 | -3 | 0.772 |
TSSK2 |
0.689 | -0.049 | -5 | 0.802 |
NEK11 |
0.689 | -0.090 | 1 | 0.674 |
PIM1 |
0.688 | -0.028 | -3 | 0.707 |
PLK3 |
0.687 | -0.044 | 2 | 0.785 |
HUNK |
0.687 | -0.119 | 2 | 0.734 |
MEK2 |
0.687 | -0.128 | 2 | 0.728 |
GRK7 |
0.686 | -0.027 | 1 | 0.618 |
GRK1 |
0.686 | -0.025 | -2 | 0.734 |
CAMK2B |
0.686 | 0.008 | 2 | 0.829 |
P38A |
0.686 | -0.027 | 1 | 0.568 |
JNK3 |
0.686 | -0.036 | 1 | 0.512 |
STLK3 |
0.686 | -0.055 | 1 | 0.688 |
TSSK1 |
0.686 | -0.048 | -3 | 0.778 |
IKKA |
0.685 | -0.055 | -2 | 0.656 |
PKCA |
0.685 | 0.061 | 2 | 0.661 |
DAPK3 |
0.685 | -0.021 | -3 | 0.711 |
PBK |
0.685 | -0.035 | 1 | 0.690 |
LOK |
0.685 | -0.019 | -2 | 0.638 |
NDR2 |
0.685 | -0.044 | -3 | 0.788 |
SRPK1 |
0.684 | -0.007 | -3 | 0.655 |
TTBK1 |
0.684 | 0.020 | 2 | 0.620 |
ROCK2 |
0.684 | -0.002 | -3 | 0.743 |
P70S6KB |
0.683 | -0.058 | -3 | 0.706 |
NEK3 |
0.683 | 0.025 | 1 | 0.704 |
NIM1 |
0.683 | -0.032 | 3 | 0.675 |
LATS2 |
0.683 | -0.016 | -5 | 0.724 |
AMPKA2 |
0.683 | -0.057 | -3 | 0.748 |
P38B |
0.683 | -0.026 | 1 | 0.496 |
NDR1 |
0.683 | -0.048 | -3 | 0.776 |
PASK |
0.683 | -0.101 | -3 | 0.772 |
PRKD1 |
0.682 | -0.029 | -3 | 0.727 |
CHAK1 |
0.682 | -0.076 | 2 | 0.695 |
DYRK2 |
0.682 | -0.022 | 1 | 0.574 |
RSK2 |
0.682 | -0.037 | -3 | 0.670 |
CAMK4 |
0.681 | -0.070 | -3 | 0.739 |
HIPK4 |
0.681 | -0.050 | 1 | 0.710 |
PHKG1 |
0.680 | 0.023 | -3 | 0.751 |
CDK18 |
0.680 | 0.055 | 1 | 0.470 |
CDK5 |
0.680 | -0.007 | 1 | 0.570 |
P90RSK |
0.680 | -0.050 | -3 | 0.679 |
DMPK1 |
0.680 | -0.011 | -3 | 0.664 |
CLK4 |
0.680 | -0.022 | -3 | 0.673 |
PKCH |
0.680 | 0.011 | 2 | 0.659 |
MELK |
0.680 | -0.045 | -3 | 0.727 |
PKCG |
0.679 | 0.024 | 2 | 0.685 |
MAPKAPK2 |
0.679 | -0.018 | -3 | 0.664 |
ERK2 |
0.679 | -0.039 | 1 | 0.517 |
KIS |
0.679 | -0.003 | 1 | 0.579 |
ERK7 |
0.679 | 0.057 | 2 | 0.559 |
CDK14 |
0.679 | 0.068 | 1 | 0.505 |
JNK2 |
0.679 | -0.040 | 1 | 0.467 |
PIM2 |
0.679 | -0.012 | -3 | 0.651 |
ULK1 |
0.679 | -0.132 | -3 | 0.707 |
PKCZ |
0.679 | -0.021 | 2 | 0.713 |
DCAMKL1 |
0.678 | -0.056 | -3 | 0.711 |
MARK2 |
0.678 | -0.037 | 4 | 0.592 |
CDK8 |
0.678 | -0.043 | 1 | 0.559 |
GSK3B |
0.678 | -0.033 | 4 | 0.404 |
PAK3 |
0.678 | -0.065 | -2 | 0.617 |
QIK |
0.678 | -0.072 | -3 | 0.739 |
SRPK2 |
0.677 | 0.004 | -3 | 0.589 |
PAK1 |
0.677 | -0.057 | -2 | 0.618 |
PKACG |
0.677 | -0.053 | -2 | 0.595 |
CDK7 |
0.677 | -0.032 | 1 | 0.546 |
CDK16 |
0.676 | 0.087 | 1 | 0.436 |
PKCB |
0.676 | -0.004 | 2 | 0.670 |
PAK2 |
0.676 | -0.082 | -2 | 0.611 |
BUB1 |
0.675 | 0.032 | -5 | 0.762 |
CAMK2A |
0.675 | -0.039 | 2 | 0.833 |
RIPK2 |
0.675 | -0.046 | 1 | 0.660 |
SGK3 |
0.675 | -0.027 | -3 | 0.727 |
QSK |
0.675 | -0.048 | 4 | 0.659 |
CDK13 |
0.675 | -0.035 | 1 | 0.512 |
MAPKAPK5 |
0.675 | -0.040 | -3 | 0.655 |
GRK2 |
0.675 | -0.092 | -2 | 0.652 |
RSK3 |
0.675 | -0.056 | -3 | 0.678 |
SLK |
0.675 | -0.055 | -2 | 0.596 |
MYLK4 |
0.675 | -0.058 | -2 | 0.615 |
AAK1 |
0.674 | 0.019 | 1 | 0.531 |
PRKD2 |
0.674 | -0.026 | -3 | 0.669 |
CLK1 |
0.674 | -0.009 | -3 | 0.639 |
NUAK1 |
0.674 | -0.046 | -3 | 0.711 |
HIPK1 |
0.674 | -0.027 | 1 | 0.591 |
ERK1 |
0.674 | -0.031 | 1 | 0.481 |
MSK2 |
0.674 | -0.059 | -3 | 0.665 |
PRKD3 |
0.673 | -0.042 | -3 | 0.635 |
MARK3 |
0.673 | -0.041 | 4 | 0.635 |
ROCK1 |
0.673 | -0.005 | -3 | 0.698 |
AURB |
0.673 | -0.028 | -2 | 0.515 |
MNK2 |
0.673 | -0.037 | -2 | 0.637 |
P38G |
0.673 | -0.030 | 1 | 0.399 |
DCAMKL2 |
0.673 | -0.062 | -3 | 0.703 |
PLK4 |
0.673 | -0.070 | 2 | 0.571 |
MRCKB |
0.673 | -0.009 | -3 | 0.664 |
MRCKA |
0.672 | -0.031 | -3 | 0.695 |
PKCT |
0.672 | 0.016 | 2 | 0.658 |
GSK3A |
0.672 | -0.023 | 4 | 0.410 |
AURA |
0.672 | -0.028 | -2 | 0.496 |
AKT2 |
0.672 | -0.021 | -3 | 0.593 |
SIK |
0.671 | -0.050 | -3 | 0.674 |
DRAK1 |
0.671 | -0.092 | 1 | 0.519 |
PLK2 |
0.671 | -0.031 | -3 | 0.708 |
PKG2 |
0.671 | -0.029 | -2 | 0.530 |
MSK1 |
0.671 | -0.040 | -3 | 0.685 |
CDK17 |
0.671 | 0.010 | 1 | 0.410 |
MARK1 |
0.671 | -0.064 | 4 | 0.645 |
P38D |
0.671 | -0.028 | 1 | 0.453 |
DAPK1 |
0.670 | -0.063 | -3 | 0.692 |
DYRK1A |
0.670 | -0.042 | 1 | 0.613 |
HIPK3 |
0.670 | -0.033 | 1 | 0.589 |
CDK1 |
0.670 | -0.042 | 1 | 0.474 |
CDK2 |
0.670 | -0.057 | 1 | 0.556 |
DYRK3 |
0.669 | -0.021 | 1 | 0.602 |
MNK1 |
0.669 | -0.037 | -2 | 0.648 |
CDK19 |
0.668 | -0.045 | 1 | 0.514 |
AKT1 |
0.668 | -0.005 | -3 | 0.629 |
CDK12 |
0.668 | -0.037 | 1 | 0.482 |
PKCE |
0.668 | 0.031 | 2 | 0.665 |
CHK2 |
0.668 | -0.007 | -3 | 0.544 |
AURC |
0.667 | -0.031 | -2 | 0.515 |
DYRK4 |
0.667 | -0.014 | 1 | 0.492 |
PKCI |
0.667 | 0.003 | 2 | 0.693 |
PHKG2 |
0.666 | 0.040 | -3 | 0.696 |
PKACB |
0.666 | -0.029 | -2 | 0.528 |
HASPIN |
0.666 | -0.037 | -1 | 0.571 |
BRSK2 |
0.665 | -0.084 | -3 | 0.738 |
CDK9 |
0.664 | -0.057 | 1 | 0.511 |
CDK6 |
0.664 | 0.003 | 1 | 0.492 |
CDK4 |
0.664 | -0.008 | 1 | 0.483 |
CAMK1D |
0.664 | -0.059 | -3 | 0.616 |
JNK1 |
0.664 | -0.058 | 1 | 0.452 |
CAMK1G |
0.663 | -0.073 | -3 | 0.650 |
CK1D |
0.663 | -0.032 | -3 | 0.420 |
SSTK |
0.662 | -0.084 | 4 | 0.656 |
SNRK |
0.662 | -0.132 | 2 | 0.614 |
PAK6 |
0.661 | -0.029 | -2 | 0.552 |
RSK4 |
0.661 | -0.065 | -3 | 0.663 |
STK33 |
0.661 | -0.096 | 2 | 0.608 |
DYRK1B |
0.660 | -0.049 | 1 | 0.512 |
MOK |
0.660 | -0.027 | 1 | 0.608 |
BRSK1 |
0.660 | -0.098 | -3 | 0.721 |
CLK2 |
0.660 | -0.013 | -3 | 0.665 |
HIPK2 |
0.659 | -0.036 | 1 | 0.488 |
CDK3 |
0.659 | -0.027 | 1 | 0.429 |
CRIK |
0.659 | -0.045 | -3 | 0.618 |
P70S6K |
0.658 | -0.071 | -3 | 0.630 |
MAK |
0.658 | -0.025 | -2 | 0.568 |
GRK3 |
0.658 | -0.087 | -2 | 0.626 |
PKACA |
0.656 | -0.035 | -2 | 0.477 |
CK1E |
0.656 | -0.058 | -3 | 0.469 |
SGK1 |
0.655 | -0.041 | -3 | 0.549 |
CDK10 |
0.655 | -0.000 | 1 | 0.486 |
CK1G1 |
0.655 | -0.050 | -3 | 0.488 |
PKN1 |
0.655 | -0.011 | -3 | 0.632 |
SBK |
0.654 | -0.031 | -3 | 0.472 |
CK2A2 |
0.654 | -0.047 | 1 | 0.522 |
PRKX |
0.654 | -0.025 | -3 | 0.642 |
CK1A2 |
0.653 | -0.057 | -3 | 0.418 |
CAMK1A |
0.648 | -0.067 | -3 | 0.567 |
PAK5 |
0.646 | -0.057 | -2 | 0.481 |
CK2A1 |
0.645 | -0.057 | 1 | 0.489 |
AKT3 |
0.645 | -0.032 | -3 | 0.549 |
PKG1 |
0.642 | -0.032 | -2 | 0.469 |
YANK3 |
0.640 | -0.052 | 2 | 0.442 |
PAK4 |
0.637 | -0.071 | -2 | 0.486 |
YANK2 |
0.631 | -0.044 | 2 | 0.468 |
CK1G3 |
0.624 | -0.043 | -3 | 0.313 |
CK1A |
0.610 | -0.075 | -3 | 0.349 |
CK1G2 |
0.599 | -0.064 | -3 | 0.408 |